ONTOLOGY REPORT - ANNOTATIONS
| Term: | dexamethasone |
|
| Accession: | CHEBI:41879
|
browse the term
|
| Definition: | A fluorinated steroid that has formula C22H29FO5. |
| Synonyms: | exact_synonym: | 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione |
| | related_synonym: | 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 9alpha-Fluoro-16alpha-methylprednisolone; C22H29FO5; Decadron; InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1; InChIKey=UREBDLICKHMUKA-CXSFZGCWSA-N; [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C; dexametasona; dexamethasonum |
| | alt_id: | CHEBI:41873; CHEBI:4461 |
| | xref_casrn: | 50-02-2 |
| | xref: | Beilstein:2066652 "Beilstein Registry Number"; ChEMBL:465281 "ChEMBL COMPOUND"; ChemIDplus:50-02-2 "CAS Registry Number"; DrugBank:DB01234 "DrugBank"; KEGG DRUG:D00292 "KEGG DRUG" |
| | xref_mesh: | MESH:D003907 |
| | xref: | Patent:DE1113690 "Patent"; Patent:GB869511 "Patent"; Patent:US3007923 "Patent"; Wikipedia:Dexamethasone "Wikipedia" |
|
|
dexamethasone
|
| G |
A2M |
alpha-2-macroglobulin |
|
decreases expression |
ISO |
12 |
9,220,304 |
9,268,558 |
RGD:6480464 |
CTD |
| G |
ABCA1 |
ATP-binding cassette, sub-family A (ABC1), member 1 |
|
increases expression |
ISO |
9 |
107,543,283 |
107,690,527 |
RGD:6480464 |
CTD |
| G |
ABCA1 |
ATP-binding cassette, sub-family A (ABC1), member 1 |
|
multiple interactions |
ISO |
9 |
107,543,283 |
107,690,527 |
RGD:6480464 |
CTD |
| G |
ABCA1 |
ATP-binding cassette, sub-family A (ABC1), member 1 |
|
multiple interactions |
ISO |
9 |
107,543,283 |
107,690,527 |
RGD:6480464 |
CTD |
| G |
ABCB1 |
ATP-binding cassette, sub-family B (MDR/TAP), member 1 |
|
increases expression |
EXP |
7 |
87,133,179 |
87,342,639 |
RGD:6480464 |
CTD |
| G |
ABCB1 |
ATP-binding cassette, sub-family B (MDR/TAP), member 1 |
|
decreases activity |
EXP |
7 |
87,133,179 |
87,342,639 |
RGD:6480464 |
CTD |
| G |
ABCB1 |
ATP-binding cassette, sub-family B (MDR/TAP), member 1 |
|
increases expression |
ISO |
7 |
87,133,179 |
87,342,639 |
RGD:6480464 |
CTD |
| G |
ABCB4 |
ATP-binding cassette, sub-family B (MDR/TAP), member 4 |
|
increases expression |
ISO |
7 |
87,031,361 |
87,105,019 |
RGD:6480464 |
CTD |
| G |
ABCC1 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 |
|
multiple interactions |
ISO |
16 |
16,043,434 |
16,236,931 |
RGD:6480464 |
CTD |
| G |
ABCC2 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 |
|
decreases expression |
ISO |
10 |
101,542,463 |
101,611,662 |
RGD:6480464 |
CTD |
| G |
ABCC2 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 |
|
multiple interactions |
ISO |
10 |
101,542,463 |
101,611,662 |
RGD:6480464 |
CTD |
| G |
ABCC2 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 |
|
increases expression |
ISO |
10 |
101,542,463 |
101,611,662 |
RGD:6480464 |
CTD |
| G |
ABCC2 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 |
|
increases expression |
ISO |
10 |
101,542,463 |
101,611,662 |
RGD:6480464 |
CTD |
| G |
ABCC3 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 |
|
multiple interactions |
EXP |
17 |
48,712,218 |
48,769,063 |
RGD:6480464 |
CTD |
| G |
ABCC3 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 |
|
increases activity |
EXP |
17 |
48,712,218 |
48,769,063 |
RGD:6480464 |
CTD |
| G |
ABCC3 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 |
|
increases expression |
EXP |
17 |
48,712,218 |
48,769,063 |
RGD:6480464 |
CTD |
| G |
ABCC3 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 |
|
affects expression |
ISO |
17 |
48,712,218 |
48,769,063 |
RGD:6480464 |
CTD |
| G |
ABCC3 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 |
|
decreases expression |
ISO |
17 |
48,712,218 |
48,769,063 |
RGD:6480464 |
CTD |
| G |
ABCC3 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 |
|
multiple interactions |
ISO |
17 |
48,712,218 |
48,769,063 |
RGD:6480464 |
CTD |
| G |
ABCC3 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 |
|
increases expression |
ISO |
17 |
48,712,218 |
48,769,063 |
RGD:6480464 |
CTD |
| G |
ABCC6 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 6 |
|
affects expression |
ISO |
16 |
16,243,422 |
16,317,328 |
RGD:6480464 |
CTD |
| G |
ABCC6 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 6 |
|
decreases expression |
ISO |
16 |
16,243,422 |
16,317,328 |
RGD:6480464 |
CTD |
| G |
ABCG2 |
ATP-binding cassette, sub-family G (WHITE), member 2 |
|
multiple interactions |
EXP |
4 |
89,011,416 |
89,152,474 |
RGD:6480464 |
CTD |
| G |
ABHD1 |
abhydrolase domain containing 1 |
|
increases expression |
ISO |
2 |
27,346,657 |
27,353,680 |
RGD:6480464 |
CTD |
| G |
ABHD1 |
abhydrolase domain containing 1 |
|
multiple interactions |
ISO |
2 |
27,346,657 |
27,353,680 |
RGD:6480464 |
CTD |
| G |
ACADM |
acyl-CoA dehydrogenase, C-4 to C-12 straight chain |
|
decreases expression |
ISO |
1 |
76,190,043 |
76,229,355 |
RGD:6480464 |
CTD |
| G |
ACAN |
aggrecan |
|
multiple interactions |
EXP |
15 |
89,346,674 |
89,418,585 |
RGD:6480464 |
CTD |
| G |
ACAN |
aggrecan |
|
increases expression |
EXP |
15 |
89,346,674 |
89,418,585 |
RGD:6480464 |
CTD |
| G |
ACE |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
increases expression |
ISO |
17 |
61,554,422 |
61,575,741 |
RGD:6480464 |
CTD |
| G |
ACE |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
multiple interactions |
ISO |
17 |
61,554,422 |
61,575,741 |
RGD:6480464 |
CTD |
| G |
ACLY |
ATP citrate lyase |
|
decreases expression |
ISO |
17 |
40,023,179 |
40,075,272 |
RGD:6480464 |
CTD |
| G |
ACO2 |
aconitase 2, mitochondrial |
|
decreases expression |
ISO |
22 |
41,865,129 |
41,924,993 |
RGD:6480464 |
CTD |
| G |
ACO2 |
aconitase 2, mitochondrial |
|
multiple interactions |
ISO |
22 |
41,865,129 |
41,924,993 |
RGD:6480464 |
CTD |
| G |
ACOT7 |
acyl-CoA thioesterase 7 |
|
decreases expression |
ISO |
1 |
6,324,332 |
6,453,826 |
RGD:6480464 |
CTD |
| G |
ACOX1 |
acyl-CoA oxidase 1, palmitoyl |
|
decreases expression |
ISO |
17 |
73,937,588 |
73,975,515 |
RGD:6480464 |
CTD |
| G |
ACP5 |
acid phosphatase 5, tartrate resistant |
|
multiple interactions |
EXP |
19 |
11,685,475 |
11,689,801 |
RGD:6480464 |
CTD |
| G |
ACSL1 |
acyl-CoA synthetase long-chain family member 1 |
|
multiple interactions |
ISO |
4 |
185,676,749 |
185,747,215 |
RGD:6480464 |
CTD |
| G |
ACSL1 |
acyl-CoA synthetase long-chain family member 1 |
|
decreases expression |
ISO |
4 |
185,676,749 |
185,747,215 |
RGD:6480464 |
CTD |
| G |
ACSL4 |
acyl-CoA synthetase long-chain family member 4 |
|
multiple interactions |
ISO |
X |
108,884,564 |
108,976,621 |
RGD:6480464 |
CTD |
| G |
ACSL4 |
acyl-CoA synthetase long-chain family member 4 |
|
increases expression |
ISO |
X |
108,884,564 |
108,976,621 |
RGD:6480464 |
CTD |
| G |
ACSL4 |
acyl-CoA synthetase long-chain family member 4 |
|
multiple interactions |
ISO |
X |
108,884,564 |
108,976,621 |
RGD:6480464 |
CTD |
| G |
ACTA2 |
actin, alpha 2, smooth muscle, aorta |
|
multiple interactions |
ISO |
10 |
90,694,831 |
90,751,147 |
RGD:6480464 |
CTD |
| G |
ACTA2 |
actin, alpha 2, smooth muscle, aorta |
|
decreases expression |
ISO |
10 |
90,694,831 |
90,751,147 |
RGD:6480464 |
CTD |
| G |
ACTB |
actin, beta |
|
multiple interactions |
ISO |
7 |
5,566,779 |
5,570,232 |
RGD:6480464 |
CTD |
| G |
ACTC1 |
actin, alpha, cardiac muscle 1 |
|
multiple interactions |
ISO |
15 |
35,080,297 |
35,087,927 |
RGD:6480464 |
CTD |
| G |
ACTG2 |
actin, gamma 2, smooth muscle, enteric |
|
multiple interactions |
ISO |
2 |
74,120,093 |
74,146,780 |
RGD:6480464 |
CTD |
| G |
ADAM12 |
ADAM metallopeptidase domain 12 |
|
multiple interactions |
ISO |
10 |
127,702,898 |
128,077,127 |
RGD:6480464 |
CTD |
| G |
ADAM17 |
ADAM metallopeptidase domain 17 |
|
decreases expression |
ISO |
2 |
9,629,392 |
9,695,917 |
RGD:6480464 |
CTD |
| G |
ADAMTS1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
|
multiple interactions |
ISO |
21 |
28,208,606 |
28,217,728 |
RGD:6480464 |
CTD |
| G |
ADH1C |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
|
increases expression |
ISO |
4 |
100,257,649 |
100,273,917 |
RGD:6480464 |
CTD |
| G |
ADH1C |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
|
multiple interactions |
ISO |
4 |
100,257,649 |
100,273,917 |
RGD:6480464 |
CTD |
| G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
|
multiple interactions |
ISO |
3 |
186,560,463 |
186,576,252 |
RGD:6480464 |
CTD |
| G |
ADM |
adrenomedullin |
|
multiple interactions |
ISO |
11 |
10,326,642 |
10,328,923 |
RGD:6480464 |
CTD |
| G |
ADORA3 |
adenosine A3 receptor |
|
increases expression |
ISO |
1 |
112,025,970 |
112,106,597 |
RGD:6480464 |
CTD |
| G |
ADRA1B |
adrenoceptor alpha 1B |
|
increases expression |
EXP |
5 |
159,343,740 |
159,400,017 |
RGD:6480464 |
CTD |
| G |
ADRA1D |
adrenoceptor alpha 1D |
|
increases expression |
EXP |
20 |
4,201,278 |
4,229,659 |
RGD:6480464 |
CTD |
| G |
ADRB2 |
adrenoceptor beta 2, surface |
|
increases expression |
ISO |
5 |
148,206,156 |
148,208,197 |
RGD:6480464 |
CTD |
| G |
ADRB2 |
adrenoceptor beta 2, surface |
|
multiple interactions |
ISO |
5 |
148,206,156 |
148,208,197 |
RGD:6480464 |
CTD |
| G |
ADRB2 |
adrenoceptor beta 2, surface |
|
multiple interactions |
ISO |
5 |
148,206,156 |
148,208,197 |
RGD:6480464 |
CTD |
| G |
ADRB3 |
adrenoceptor beta 3 |
|
decreases expression |
ISO |
8 |
37,820,513 |
37,824,184 |
RGD:6480464 |
CTD |
| G |
AGR2 |
anterior gradient 2 homolog (Xenopus laevis) |
|
multiple interactions |
EXP |
7 |
16,832,264 |
16,844,738 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
ISO |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
increases expression |
ISO |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
ISO |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
ISO |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
ISO |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AHR |
aryl hydrocarbon receptor |
|
multiple interactions |
EXP |
7 |
17,338,276 |
17,385,775 |
RGD:6480464 |
CTD |
| G |
AHR |
aryl hydrocarbon receptor |
|
multiple interactions |
EXP |
7 |
17,338,276 |
17,385,775 |
RGD:6480464 |
CTD |
| G |
AHR |
aryl hydrocarbon receptor |
|
decreases expression |
EXP |
7 |
17,338,276 |
17,385,775 |
RGD:6480464 |
CTD |
| G |
AHR |
aryl hydrocarbon receptor |
|
multiple interactions |
EXP |
7 |
17,338,276 |
17,385,775 |
RGD:6480464 |
CTD |
| G |
AHR |
aryl hydrocarbon receptor |
|
decreases expression |
EXP |
7 |
17,338,276 |
17,385,775 |
RGD:6480464 |
CTD |
| G |
AHR |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
7 |
17,338,276 |
17,385,775 |
RGD:6480464 |
CTD |
| G |
AHR |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
7 |
17,338,276 |
17,385,775 |
RGD:6480464 |
CTD |
| G |
AHR |
aryl hydrocarbon receptor |
|
increases expression |
ISO |
7 |
17,338,276 |
17,385,775 |
RGD:6480464 |
CTD |
| G |
AHR |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
7 |
17,338,276 |
17,385,775 |
RGD:6480464 |
CTD |
| G |
AHSA1 |
AHA1, activator of heat shock 90kDa protein ATPase homolog 1 (yeast) |
|
increases expression |
ISO |
14 |
77,924,373 |
77,935,815 |
RGD:6480464 |
CTD |
| G |
AHSG |
alpha-2-HS-glycoprotein |
|
increases response to substance |
EXP |
3 |
186,330,850 |
186,339,107 |
RGD:6480464 |
CTD |
| G |
AIFM1 |
apoptosis-inducing factor, mitochondrion-associated, 1 |
|
multiple interactions |
ISO |
X |
129,263,337 |
129,299,861 |
RGD:6480464 |
CTD |
| G |
AIM1 |
absent in melanoma 1 |
|
increases expression |
EXP |
6 |
106,959,730 |
107,018,335 |
RGD:6480464 |
CTD |
| G |
AKAP12 |
A kinase (PRKA) anchor protein 12 |
|
multiple interactions |
ISO |
6 |
151,561,134 |
151,679,694 |
RGD:6480464 |
CTD |
| G |
AKAP7 |
A kinase (PRKA) anchor protein 7 |
|
multiple interactions |
EXP |
6 |
131,456,826 |
131,604,675 |
RGD:6480464 |
CTD |
| G |
AKR1CL1 |
aldo-keto reductase family 1, member C-like 1 |
|
multiple interactions |
ISO |
10 |
5,196,655 |
5,227,150 |
RGD:6480464 |
CTD |
| G |
AKR1CL1 |
aldo-keto reductase family 1, member C-like 1 |
|
increases expression |
ISO |
10 |
5,196,655 |
5,227,150 |
RGD:6480464 |
CTD |
| G |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
decreases phosphorylation |
EXP |
14 |
105,235,686 |
105,262,080 |
RGD:6480464 |
CTD |
| G |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
decreases phosphorylation |
ISO |
14 |
105,235,686 |
105,262,080 |
RGD:6480464 |
CTD |
| G |
ALB |
albumin |
|
multiple interactions |
EXP |
4 |
74,269,972 |
74,287,129 |
RGD:6480464 |
CTD |
| G |
ALB |
albumin |
|
multiple interactions |
EXP |
4 |
74,269,972 |
74,287,129 |
RGD:6480464 |
CTD |
| G |
ALB |
albumin |
|
increases expression |
ISO |
4 |
74,269,972 |
74,287,129 |
RGD:6480464 |
CTD |
| G |
ALB |
albumin |
|
increases secretion |
ISO |
4 |
74,269,972 |
74,287,129 |
RGD:6480464 |
CTD |
| G |
ALDH1A1 |
aldehyde dehydrogenase 1 family, member A1 |
|
affects expression |
ISO |
9 |
75,515,578 |
75,568,233 |
RGD:6480464 |
CTD |
| G |
ALDH1B1 |
aldehyde dehydrogenase 1 family, member B1 |
|
affects expression |
ISO |
9 |
38,392,661 |
38,398,662 |
RGD:6480464 |
CTD |
| G |
ALDOA |
aldolase A, fructose-bisphosphate |
|
increases expression |
ISO |
16 |
30,064,411 |
30,081,741 |
RGD:6480464 |
CTD |
| G |
ALOX5 |
arachidonate 5-lipoxygenase |
|
multiple interactions |
ISO |
10 |
45,869,624 |
45,941,567 |
RGD:6480464 |
CTD |
| G |
ALPL |
alkaline phosphatase, liver/bone/kidney |
|
multiple interactions |
ISO |
1 |
21,835,858 |
21,904,905 |
RGD:6480464 |
CTD |
| G |
AMPD3 |
adenosine monophosphate deaminase 3 |
|
increases expression |
ISO |
11 |
10,471,868 |
10,529,126 |
RGD:6480464 |
CTD |
| G |
AMPD3 |
adenosine monophosphate deaminase 3 |
|
multiple interactions |
ISO |
11 |
10,471,868 |
10,529,126 |
RGD:6480464 |
CTD |
| G |
AMY1A |
amylase, alpha 1A (salivary) |
|
increases expression |
ISO |
1 |
104,198,141 |
104,207,173 |
RGD:6480464 |
CTD |
| G |
ANGPT1 |
angiopoietin 1 |
|
multiple interactions |
EXP |
8 |
108,261,710 |
108,510,254 |
RGD:6480464 |
CTD |
| G |
ANGPTL4 |
angiopoietin-like 4 |
|
increases expression |
ISO |
19 |
8,429,011 |
8,439,257 |
RGD:6480464 |
CTD |
| G |
ANGPTL4 |
angiopoietin-like 4 |
|
affects response to substance |
ISO |
19 |
8,429,011 |
8,439,257 |
RGD:6480464 |
CTD |
| G |
ANGPTL4 |
angiopoietin-like 4 |
|
multiple interactions |
ISO |
19 |
8,429,011 |
8,439,257 |
RGD:6480464 |
CTD |
| G |
ANGPTL4 |
angiopoietin-like 4 |
|
increases expression |
ISO |
19 |
8,429,011 |
8,439,257 |
RGD:6480464 |
CTD |
| G |
ANGPTL4 |
angiopoietin-like 4 |
|
multiple interactions |
ISO |
19 |
8,429,011 |
8,439,257 |
RGD:6480464 |
CTD |
| G |
ANK1 |
ankyrin 1, erythrocytic |
|
decreases expression |
ISO |
8 |
41,510,744 |
41,754,280 |
RGD:6480464 |
CTD |
| G |
ANK1 |
ankyrin 1, erythrocytic |
|
multiple interactions |
ISO |
8 |
41,510,744 |
41,754,280 |
RGD:6480464 |
CTD |
| G |
ANXA1 |
annexin A1 |
|
multiple interactions |
EXP |
9 |
75,766,781 |
75,785,307 |
RGD:6480464 |
CTD |
| G |
ANXA1 |
annexin A1 |
|
multiple interactions |
EXP |
9 |
75,766,781 |
75,785,307 |
RGD:6480464 |
CTD |
| G |
ANXA1 |
annexin A1 |
|
increases expression |
EXP |
9 |
75,766,781 |
75,785,307 |
RGD:6480464 |
CTD |
| G |
ANXA1 |
annexin A1 |
|
increases localization |
EXP |
9 |
75,766,781 |
75,785,307 |
RGD:6480464 |
CTD |
| G |
ANXA1 |
annexin A1 |
|
increases phosphorylation |
EXP |
9 |
75,766,781 |
75,785,307 |
RGD:6480464 |
CTD |
| G |
ANXA1 |
annexin A1 |
|
affects response to substance |
ISO |
9 |
75,766,781 |
75,785,307 |
RGD:6480464 |
CTD |
| G |
ANXA1 |
annexin A1 |
|
multiple interactions |
ISO |
9 |
75,766,781 |
75,785,307 |
RGD:6480464 |
CTD |
| G |
ANXA1 |
annexin A1 |
|
affects response to substance |
ISO |
9 |
75,766,781 |
75,785,307 |
RGD:6480464 |
CTD |
| G |
ANXA3 |
annexin A3 |
|
multiple interactions |
ISO |
4 |
79,472,742 |
79,531,605 |
RGD:6480464 |
CTD |
| G |
ANXA6 |
annexin A6 |
|
multiple interactions |
ISO |
5 |
150,480,267 |
150,537,443 |
RGD:6480464 |
CTD |
| G |
ANXA8 |
annexin A8 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
AOX1 |
aldehyde oxidase 1 |
|
multiple interactions |
ISO |
2 |
201,450,731 |
201,536,218 |
RGD:6480464 |
CTD |
| G |
AOX1 |
aldehyde oxidase 1 |
|
increases expression |
ISO |
2 |
201,450,731 |
201,536,218 |
RGD:6480464 |
CTD |
| G |
AP1G2 |
adaptor-related protein complex 1, gamma 2 subunit |
|
increases expression |
EXP |
14 |
24,028,777 |
24,037,279 |
RGD:6480464 |
CTD |
| G |
APCDD1 |
adenomatosis polyposis coli down-regulated 1 |
|
multiple interactions |
ISO |
18 |
10,454,625 |
10,488,698 |
RGD:6480464 |
CTD |
| G |
APLN |
apelin |
|
decreases expression |
ISO |
X |
128,779,236 |
128,788,933 |
RGD:6480464 |
CTD |
| G |
APLN |
apelin |
|
multiple interactions |
ISO |
X |
128,779,236 |
128,788,933 |
RGD:6480464 |
CTD |
| G |
APOA1 |
apolipoprotein A-I |
|
affects expression |
ISO |
11 |
116,706,469 |
116,708,338 |
RGD:6480464 |
CTD |
| G |
APOA4 |
apolipoprotein A-IV |
|
affects expression |
ISO |
11 |
116,691,418 |
116,694,011 |
RGD:6480464 |
CTD |
| G |
APOB |
apolipoprotein B (including Ag(x) antigen) |
|
increases expression |
ISO |
2 |
21,224,301 |
21,266,945 |
RGD:6480464 |
CTD |
| G |
APOC3 |
apolipoprotein C-III |
|
increases expression |
ISO |
11 |
116,700,624 |
116,703,787 |
RGD:6480464 |
CTD |
| G |
APOC3 |
apolipoprotein C-III |
|
multiple interactions |
ISO |
11 |
116,700,624 |
116,703,787 |
RGD:6480464 |
CTD |
| G |
APOC3 |
apolipoprotein C-III |
|
increases expression |
ISO |
11 |
116,700,624 |
116,703,787 |
RGD:6480464 |
CTD |
| G |
APOC3 |
apolipoprotein C-III |
|
multiple interactions |
ISO |
11 |
116,700,624 |
116,703,787 |
RGD:6480464 |
CTD |
| G |
AQP7 |
aquaporin 7 |
|
increases expression |
ISO |
9 |
33,384,948 |
33,402,517 |
RGD:6480464 |
CTD |
| G |
AR |
androgen receptor |
|
affects activity |
EXP |
X |
66,763,874 |
66,950,461 |
RGD:6480464 |
CTD |
| G |
AR |
androgen receptor |
|
affects binding |
EXP |
X |
66,763,874 |
66,950,461 |
RGD:6480464 |
CTD |
| G |
AR |
androgen receptor |
|
multiple interactions |
ISO |
X |
66,763,874 |
66,950,461 |
RGD:6480464 |
CTD |
| G |
AR |
androgen receptor |
|
decreases expression |
EXP |
X |
66,763,874 |
66,950,461 |
RGD:6480464 |
CTD |
| G |
AR |
androgen receptor |
|
affects binding |
ISO |
X |
66,763,874 |
66,950,461 |
RGD:6480464 |
CTD |
| G |
ARAF |
v-raf murine sarcoma 3611 viral oncogene homolog |
|
multiple interactions |
EXP |
X |
47,420,499 |
47,431,320 |
RGD:6480464 |
CTD |
| G |
AREG |
amphiregulin |
|
decreases expression |
ISO |
4 |
75,310,853 |
75,320,726 |
RGD:6480464 |
CTD |
| G |
ARG2 |
arginase, type II |
|
increases expression |
ISO |
14 |
68,086,579 |
68,118,437 |
RGD:6480464 |
CTD |
| G |
ARG2 |
arginase, type II |
|
multiple interactions |
ISO |
14 |
68,086,579 |
68,118,437 |
RGD:6480464 |
CTD |
| G |
ARHGAP10 |
Rho GTPase activating protein 10 |
|
increases expression |
ISO |
4 |
148,653,453 |
148,993,927 |
RGD:6480464 |
CTD |
| G |
ARHGAP30 |
Rho GTPase activating protein 30 |
|
increases expression |
ISO |
1 |
161,016,732 |
161,039,760 |
RGD:6480464 |
CTD |
| G |
ARHGAP5 |
Rho GTPase activating protein 5 |
|
multiple interactions |
ISO |
14 |
32,546,495 |
32,628,934 |
RGD:6480464 |
CTD |
| G |
ARNT |
aryl hydrocarbon receptor nuclear translocator |
|
increases expression |
ISO |
1 |
150,782,181 |
150,849,244 |
RGD:6480464 |
CTD |
| G |
ART1 |
ADP-ribosyltransferase 1 |
|
multiple interactions |
ISO |
11 |
3,666,361 |
3,685,646 |
RGD:6480464 |
CTD |
| G |
ART1 |
ADP-ribosyltransferase 1 |
|
increases expression |
ISO |
11 |
3,666,361 |
3,685,646 |
RGD:6480464 |
CTD |
| G |
ART5 |
ADP-ribosyltransferase 5 |
|
increases expression |
ISO |
11 |
3,659,736 |
3,663,546 |
RGD:6480464 |
CTD |
| G |
ART5 |
ADP-ribosyltransferase 5 |
|
multiple interactions |
ISO |
11 |
3,659,736 |
3,663,546 |
RGD:6480464 |
CTD |
| G |
ASAH2 |
N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2 |
|
decreases expression |
ISO |
10 |
51,947,000 |
52,008,370 |
RGD:6480464 |
CTD |
| G |
ASAH2 |
N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2 |
|
multiple interactions |
ISO |
10 |
51,947,000 |
52,008,370 |
RGD:6480464 |
CTD |
| G |
ASS1 |
argininosuccinate synthase 1 |
|
increases expression |
ISO |
9 |
133,320,094 |
133,376,661 |
RGD:6480464 |
CTD |
| G |
ASS1 |
argininosuccinate synthase 1 |
|
multiple interactions |
ISO |
9 |
133,320,094 |
133,376,661 |
RGD:6480464 |
CTD |
| G |
ATCAY |
ataxia, cerebellar, Cayman type |
|
decreases expression |
ISO |
19 |
3,880,618 |
3,928,080 |
RGD:6480464 |
CTD |
| G |
ATCAY |
ataxia, cerebellar, Cayman type |
|
multiple interactions |
ISO |
19 |
3,880,618 |
3,928,080 |
RGD:6480464 |
CTD |
| G |
ATP2A1 |
ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 |
|
increases expression |
ISO |
16 |
28,889,809 |
28,915,830 |
RGD:6480464 |
CTD |
| G |
AVP |
arginine vasopressin |
|
multiple interactions |
ISO |
20 |
3,063,202 |
3,065,370 |
RGD:6480464 |
CTD |
| G |
AVP |
arginine vasopressin |
|
multiple interactions |
ISO |
20 |
3,063,202 |
3,065,370 |
RGD:6480464 |
CTD |
| G |
AVP |
arginine vasopressin |
|
multiple interactions |
ISO |
20 |
3,063,202 |
3,065,370 |
RGD:6480464 |
CTD |
| G |
AVP |
arginine vasopressin |
|
increases activity |
ISO |
20 |
3,063,202 |
3,065,370 |
RGD:6480464 |
CTD |
| G |
B2M |
beta-2-microglobulin |
|
decreases expression |
EXP |
15 |
45,003,685 |
45,010,357 |
RGD:6480464 |
CTD |
| G |
B4GALT6 |
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 6 |
|
decreases expression |
ISO |
18 |
29,202,209 |
29,264,686 |
RGD:6480464 |
CTD |
| G |
B4GALT6 |
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 6 |
|
multiple interactions |
ISO |
18 |
29,202,209 |
29,264,686 |
RGD:6480464 |
CTD |
| G |
BAD |
BCL2-associated agonist of cell death |
|
decreases phosphorylation |
ISO |
11 |
64,037,300 |
64,052,176 |
RGD:6480464 |
CTD |
| G |
BAD |
BCL2-associated agonist of cell death |
|
increases expression |
ISO |
11 |
64,037,300 |
64,052,176 |
RGD:6480464 |
CTD |
| G |
BAD |
BCL2-associated agonist of cell death |
|
multiple interactions |
ISO |
11 |
64,037,300 |
64,052,176 |
RGD:6480464 |
CTD |
| G |
BAMBI |
BMP and activin membrane-bound inhibitor homolog (Xenopus laevis) |
|
decreases expression |
ISO |
10 |
28,966,424 |
28,971,868 |
RGD:6480464 |
CTD |
| G |
BASP1 |
brain abundant, membrane attached signal protein 1 |
|
decreases expression |
ISO |
5 |
17,217,750 |
17,276,943 |
RGD:6480464 |
CTD |
| G |
BASP1 |
brain abundant, membrane attached signal protein 1 |
|
multiple interactions |
ISO |
5 |
17,217,750 |
17,276,943 |
RGD:6480464 |
CTD |
| G |
BAX |
BCL2-associated X protein |
|
multiple interactions |
ISO |
19 |
49,458,117 |
49,465,055 |
RGD:6480464 |
CTD |
| G |
BAX |
BCL2-associated X protein |
|
multiple interactions |
ISO |
19 |
49,458,117 |
49,465,055 |
RGD:6480464 |
CTD |
| G |
BAX |
BCL2-associated X protein |
|
increases expression |
ISO |
19 |
49,458,117 |
49,465,055 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
increases response to substance |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
decreases response to substance |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
ISO |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
multiple interactions |
EXP |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
multiple interactions |
EXP |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
decreases expression |
EXP |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
increases expression |
EXP |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
increases expression |
EXP |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
increases stability |
EXP |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
multiple interactions |
ISO |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
multiple interactions |
ISO |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
increases expression |
ISO |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
multiple interactions |
ISO |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
increases expression |
ISO |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
increases expression |
ISO |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
multiple interactions |
ISO |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L11 |
BCL2-like 11 (apoptosis facilitator) |
|
increases response to substance |
EXP |
2 |
111,878,491 |
111,926,022 |
RGD:6480464 |
CTD |
| G |
BCL2L11 |
BCL2-like 11 (apoptosis facilitator) |
|
increases expression |
EXP |
2 |
111,878,491 |
111,926,022 |
RGD:6480464 |
CTD |
| G |
BCL2L11 |
BCL2-like 11 (apoptosis facilitator) |
|
increases phosphorylation |
EXP |
2 |
111,878,491 |
111,926,022 |
RGD:6480464 |
CTD |
| G |
BCL2L11 |
BCL2-like 11 (apoptosis facilitator) |
|
multiple interactions |
EXP |
2 |
111,878,491 |
111,926,022 |
RGD:6480464 |
CTD |
| G |
BCL2L11 |
BCL2-like 11 (apoptosis facilitator) |
|
multiple interactions |
EXP |
2 |
111,878,491 |
111,926,022 |
RGD:6480464 |
CTD |
| G |
BCL2L11 |
BCL2-like 11 (apoptosis facilitator) |
|
increases expression |
ISO |
2 |
111,878,491 |
111,926,022 |
RGD:6480464 |
CTD |
| G |
BCL2L11 |
BCL2-like 11 (apoptosis facilitator) |
|
increases expression |
ISO |
2 |
111,878,491 |
111,926,022 |
RGD:6480464 |
CTD |
| G |
BCL2L11 |
BCL2-like 11 (apoptosis facilitator) |
|
increases response to substance |
ISO |
2 |
111,878,491 |
111,926,022 |
RGD:6480464 |
CTD |
| G |
BCL3 |
B-cell CLL/lymphoma 3 |
|
decreases expression |
ISO |
19 |
45,251,978 |
45,263,301 |
RGD:6480464 |
CTD |
| G |
BCL3 |
B-cell CLL/lymphoma 3 |
|
multiple interactions |
ISO |
19 |
45,251,978 |
45,263,301 |
RGD:6480464 |
CTD |
| G |
BCR |
breakpoint cluster region |
|
decreases expression |
ISO |
22 |
23,522,552 |
23,660,224 |
RGD:6480464 |
CTD |
| G |
BCR |
breakpoint cluster region |
|
multiple interactions |
ISO |
22 |
23,522,552 |
23,660,224 |
RGD:6480464 |
CTD |
| G |
BDNF |
brain-derived neurotrophic factor |
|
decreases expression |
EXP |
11 |
27,676,440 |
27,743,605 |
RGD:6480464 |
CTD |
| G |
BHLHE41 |
basic helix-loop-helix family, member e41 |
|
multiple interactions |
ISO |
12 |
26,272,959 |
26,278,003 |
RGD:6480464 |
CTD |
| G |
BHLHE41 |
basic helix-loop-helix family, member e41 |
|
decreases expression |
ISO |
12 |
26,272,959 |
26,278,003 |
RGD:6480464 |
CTD |
| G |
BIRC2 |
baculoviral IAP repeat containing 2 |
|
multiple interactions |
EXP |
11 |
102,217,913 |
102,249,401 |
RGD:6480464 |
CTD |
| G |
BIRC3 |
baculoviral IAP repeat containing 3 |
|
multiple interactions |
EXP |
11 |
102,188,181 |
102,210,134 |
RGD:6480464 |
CTD |
| G |
BIRC3 |
baculoviral IAP repeat containing 3 |
|
increases expression |
EXP |
11 |
102,188,181 |
102,210,134 |
RGD:6480464 |
CTD |
| G |
BIRC3 |
baculoviral IAP repeat containing 3 |
|
multiple interactions |
ISO |
11 |
102,188,181 |
102,210,134 |
RGD:6480464 |
CTD |
| G |
BIRC3 |
baculoviral IAP repeat containing 3 |
|
increases expression |
ISO |
11 |
102,188,181 |
102,210,134 |
RGD:6480464 |
CTD |
| G |
BIRC3 |
baculoviral IAP repeat containing 3 |
|
increases expression |
EXP |
11 |
102,188,181 |
102,210,134 |
RGD:6480464 |
CTD |
| G |
BIRC5 |
baculoviral IAP repeat containing 5 |
|
affects expression |
EXP |
17 |
76,210,277 |
76,221,716 |
RGD:6480464 |
CTD |
| G |
BIRC5 |
baculoviral IAP repeat containing 5 |
|
multiple interactions |
EXP |
17 |
76,210,277 |
76,221,716 |
RGD:6480464 |
CTD |
| G |
BIRC5 |
baculoviral IAP repeat containing 5 |
|
multiple interactions |
EXP |
17 |
76,210,277 |
76,221,716 |
RGD:6480464 |
CTD |
| G |
BMP2 |
bone morphogenetic protein 2 |
|
multiple interactions |
EXP |
20 |
6,748,745 |
6,760,910 |
RGD:6480464 |
CTD |
| G |
BMP2 |
bone morphogenetic protein 2 |
|
multiple interactions |
EXP |
20 |
6,748,745 |
6,760,910 |
RGD:6480464 |
CTD |
| G |
BMP4 |
bone morphogenetic protein 4 |
|
multiple interactions |
EXP |
14 |
54,416,454 |
54,423,554 |
RGD:6480464 |
CTD |
| G |
BMP4 |
bone morphogenetic protein 4 |
|
affects expression |
ISO |
14 |
54,416,454 |
54,423,554 |
RGD:6480464 |
CTD |
| G |
BMP4 |
bone morphogenetic protein 4 |
|
multiple interactions |
ISO |
14 |
54,416,454 |
54,423,554 |
RGD:6480464 |
CTD |
| G |
BMP6 |
bone morphogenetic protein 6 |
|
multiple interactions |
EXP |
6 |
7,727,011 |
7,881,961 |
RGD:6480464 |
CTD |
| G |
BMP8A |
bone morphogenetic protein 8a |
|
increases expression |
ISO |
1 |
39,957,318 |
39,995,541 |
RGD:6480464 |
CTD |
| G |
BMP8A |
bone morphogenetic protein 8a |
|
decreases response to substance |
ISO |
1 |
39,957,318 |
39,995,541 |
RGD:6480464 |
CTD |
| G |
BTG1 |
B-cell translocation gene 1, anti-proliferative |
|
increases expression |
EXP |
12 |
92,534,054 |
92,539,673 |
RGD:6480464 |
CTD |
| G |
BTG2 |
BTG family, member 2 |
|
increases expression |
EXP |
1 |
203,274,664 |
203,278,730 |
RGD:6480464 |
CTD |
| G |
C1QTNF3 |
C1q and tumor necrosis factor related protein 3 |
|
decreases expression |
ISO |
5 |
34,017,963 |
34,043,371 |
RGD:6480464 |
CTD |
| G |
C1QTNF3 |
C1q and tumor necrosis factor related protein 3 |
|
multiple interactions |
ISO |
5 |
34,017,963 |
34,043,371 |
RGD:6480464 |
CTD |
| G |
C3 |
complement component 3 |
|
multiple interactions |
ISO |
19 |
6,677,846 |
6,720,662 |
RGD:6480464 |
CTD |
| G |
C4A |
complement component 4A (Rodgers blood group) |
|
multiple interactions |
ISO |
6 |
31,949,834 |
31,970,457 |
RGD:6480464 |
CTD |
| G |
C4A |
complement component 4A (Rodgers blood group) |
|
increases expression |
ISO |
6 |
31,949,834 |
31,970,457 |
RGD:6480464 |
CTD |
| G |
CA4 |
carbonic anhydrase IV |
|
decreases expression |
ISO |
17 |
58,227,302 |
58,236,907 |
RGD:6480464 |
CTD |
| G |
CA4 |
carbonic anhydrase IV |
|
multiple interactions |
ISO |
17 |
58,227,302 |
58,236,907 |
RGD:6480464 |
CTD |
| G |
CACNA2D1 |
calcium channel, voltage-dependent, alpha 2/delta subunit 1 |
|
multiple interactions |
ISO |
7 |
81,579,418 |
82,073,031 |
RGD:6480464 |
CTD |
| G |
CALB1 |
calbindin 1, 28kDa |
|
decreases expression |
ISO |
8 |
91,070,838 |
91,095,107 |
RGD:6480464 |
CTD |
| G |
CALCA |
calcitonin-related polypeptide alpha |
|
multiple interactions |
ISO |
11 |
14,988,215 |
14,993,832 |
RGD:6480464 |
CTD |
| G |
CALCA |
calcitonin-related polypeptide alpha |
|
decreases response to substance |
EXP |
11 |
14,988,215 |
14,993,832 |
RGD:6480464 |
CTD |
| G |
CALML4 |
calmodulin-like 4 |
|
multiple interactions |
ISO |
15 |
68,483,043 |
68,498,448 |
RGD:6480464 |
CTD |
| G |
CALU |
calumenin |
|
increases expression |
ISO |
7 |
128,379,346 |
128,413,477 |
RGD:6480464 |
CTD |
| G |
CAMK4 |
calcium/calmodulin-dependent protein kinase IV |
|
decreases expression |
ISO |
5 |
110,559,947 |
110,820,749 |
RGD:6480464 |
CTD |
| G |
CAMK4 |
calcium/calmodulin-dependent protein kinase IV |
|
multiple interactions |
ISO |
5 |
110,559,947 |
110,820,749 |
RGD:6480464 |
CTD |
| G |
CAPN2 |
calpain 2, (m/II) large subunit |
|
increases expression |
ISO |
1 |
223,889,295 |
223,963,720 |
RGD:6480464 |
CTD |
| G |
CAPN2 |
calpain 2, (m/II) large subunit |
|
multiple interactions |
ISO |
1 |
223,889,295 |
223,963,720 |
RGD:6480464 |
CTD |
| G |
CASP1 |
caspase 1, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
11 |
104,896,235 |
104,905,884 |
RGD:6480464 |
CTD |
| G |
CASP2 |
caspase 2, apoptosis-related cysteine peptidase |
|
decreases expression |
ISO |
7 |
142,985,308 |
143,004,789 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
decreases activity |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases activity |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases expression |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
decreases activity |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP7 |
caspase 7, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
10 |
115,438,921 |
115,490,668 |
RGD:6480464 |
CTD |
| G |
CASP8 |
caspase 8, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
2 |
202,098,166 |
202,152,434 |
RGD:6480464 |
CTD |
| G |
CASP8 |
caspase 8, apoptosis-related cysteine peptidase |
|
increases activity |
EXP |
2 |
202,098,166 |
202,152,434 |
RGD:6480464 |
CTD |
| G |
CASP8 |
caspase 8, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
2 |
202,098,166 |
202,152,434 |
RGD:6480464 |
CTD |
| G |
CASP8 |
caspase 8, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
2 |
202,098,166 |
202,152,434 |
RGD:6480464 |
CTD |
| G |
CASP8 |
caspase 8, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
2 |
202,098,166 |
202,152,434 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
EXP |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases cleavage |
EXP |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
decreases expression |
ISO |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
multiple interactions |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
multiple interactions |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
decreases activity |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
decreases expression |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
increases activity |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
decreases activity |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
decreases expression |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
increases activity |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
multiple interactions |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
increases expression |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAV1 |
caveolin 1, caveolae protein, 22kDa |
|
multiple interactions |
ISO |
7 |
116,164,839 |
116,201,239 |
RGD:6480464 |
CTD |
| G |
CAV1 |
caveolin 1, caveolae protein, 22kDa |
|
multiple interactions |
ISO |
7 |
116,164,839 |
116,201,239 |
RGD:6480464 |
CTD |
| G |
CCAR1 |
cell division cycle and apoptosis regulator 1 |
|
increases expression |
ISO |
10 |
70,480,971 |
70,551,309 |
RGD:6480464 |
CTD |
| G |
CCDC86 |
coiled-coil domain containing 86 |
|
decreases expression |
EXP |
11 |
60,609,429 |
60,618,561 |
RGD:6480464 |
CTD |
| G |
CCKBR |
cholecystokinin B receptor |
|
decreases expression |
ISO |
11 |
6,280,904 |
6,293,357 |
RGD:6480464 |
CTD |
| G |
CCKBR |
cholecystokinin B receptor |
|
multiple interactions |
ISO |
11 |
6,280,904 |
6,293,357 |
RGD:6480464 |
CTD |
| G |
CCL17 |
chemokine (C-C motif) ligand 17 |
|
multiple interactions |
ISO |
16 |
57,438,679 |
57,449,974 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
ISO |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL26 |
chemokine (C-C motif) ligand 26 |
|
multiple interactions |
EXP |
7 |
75,398,842 |
75,419,064 |
RGD:6480464 |
CTD |
| G |
CCL3 |
chemokine (C-C motif) ligand 3 |
|
multiple interactions |
ISO |
17 |
34,415,602 |
34,417,506 |
RGD:6480464 |
CTD |
| G |
CCL5 |
chemokine (C-C motif) ligand 5 |
|
multiple interactions |
EXP |
17 |
34,198,495 |
34,207,377 |
RGD:6480464 |
CTD |
| G |
CCL5 |
chemokine (C-C motif) ligand 5 |
|
multiple interactions |
ISO |
17 |
34,198,495 |
34,207,377 |
RGD:6480464 |
CTD |
| G |
CCL5 |
chemokine (C-C motif) ligand 5 |
|
multiple interactions |
ISO |
17 |
34,198,495 |
34,207,377 |
RGD:6480464 |
CTD |
| G |
CCL7 |
chemokine (C-C motif) ligand 7 |
|
multiple interactions |
ISO |
17 |
32,597,240 |
32,599,256 |
RGD:6480464 |
CTD |
| G |
CCNB1 |
cyclin B1 |
|
decreases expression |
ISO |
5 |
68,462,837 |
68,474,072 |
RGD:6480464 |
CTD |
| G |
CCNB1 |
cyclin B1 |
|
multiple interactions |
ISO |
5 |
68,462,837 |
68,474,072 |
RGD:6480464 |
CTD |
| G |
CCND1 |
cyclin D1 |
|
multiple interactions |
EXP |
11 |
69,455,873 |
69,469,242 |
RGD:6480464 |
CTD |
| G |
CCND1 |
cyclin D1 |
|
multiple interactions |
EXP |
11 |
69,455,873 |
69,469,242 |
RGD:6480464 |
CTD |
| G |
CCND1 |
cyclin D1 |
|
multiple interactions |
EXP |
11 |
69,455,873 |
69,469,242 |
RGD:6480464 |
CTD |
| G |
CCND1 |
cyclin D1 |
|
decreases expression |
EXP |
11 |
69,455,873 |
69,469,242 |
RGD:6480464 |
CTD |
| G |
CCND1 |
cyclin D1 |
|
multiple interactions |
ISO |
11 |
69,455,873 |
69,469,242 |
RGD:6480464 |
CTD |
| G |
CCND1 |
cyclin D1 |
|
multiple interactions |
ISO |
11 |
69,455,873 |
69,469,242 |
RGD:6480464 |
CTD |
| G |
CCND1 |
cyclin D1 |
|
decreases expression |
ISO |
11 |
69,455,873 |
69,469,242 |
RGD:6480464 |
CTD |
| G |
CCND1 |
cyclin D1 |
|
increases degradation |
ISO |
11 |
69,455,873 |
69,469,242 |
RGD:6480464 |
CTD |
| G |
CCND1 |
cyclin D1 |
|
increases ubiquitination |
ISO |
11 |
69,455,873 |
69,469,242 |
RGD:6480464 |
CTD |
| G |
CCND1 |
cyclin D1 |
|
multiple interactions |
ISO |
11 |
69,455,873 |
69,469,242 |
RGD:6480464 |
CTD |
| G |
CCND2 |
cyclin D2 |
|
decreases expression |
ISO |
12 |
4,382,902 |
4,414,522 |
RGD:6480464 |
CTD |
| G |
CCNG1 |
cyclin G1 |
|
increases expression |
ISO |
5 |
162,864,577 |
162,872,022 |
RGD:6480464 |
CTD |
| G |
CCR3 |
chemokine (C-C motif) receptor 3 |
|
decreases expression |
EXP |
3 |
46,283,872 |
46,308,197 |
RGD:6480464 |
CTD |
| G |
CCR4 |
chemokine (C-C motif) receptor 4 |
|
increases expression |
EXP |
3 |
32,993,066 |
32,996,403 |
RGD:6480464 |
CTD |
| G |
CCR9 |
chemokine (C-C motif) receptor 9 |
|
increases expression |
ISO |
3 |
45,927,996 |
45,944,667 |
RGD:6480464 |
CTD |
| G |
CD14 |
CD14 molecule |
|
increases expression |
EXP |
5 |
140,011,313 |
140,013,286 |
RGD:6480464 |
CTD |
| G |
CD163 |
CD163 molecule |
|
increases expression |
ISO |
12 |
7,623,412 |
7,656,414 |
RGD:6480464 |
CTD |
| G |
CD24 |
CD24 molecule |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
CD24 |
CD24 molecule |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
CD28 |
CD28 molecule |
|
multiple interactions |
EXP |
2 |
204,571,198 |
204,603,635 |
RGD:6480464 |
CTD |
| G |
CD36 |
CD36 molecule (thrombospondin receptor) |
|
increases expression |
EXP |
7 |
80,231,504 |
80,308,593 |
RGD:6480464 |
CTD |
| G |
CD36 |
CD36 molecule (thrombospondin receptor) |
|
affects expression |
ISO |
7 |
80,231,504 |
80,308,593 |
RGD:6480464 |
CTD |
| G |
CD36 |
CD36 molecule (thrombospondin receptor) |
|
multiple interactions |
ISO |
7 |
80,231,504 |
80,308,593 |
RGD:6480464 |
CTD |
| G |
CD36 |
CD36 molecule (thrombospondin receptor) |
|
increases expression |
ISO |
7 |
80,231,504 |
80,308,593 |
RGD:6480464 |
CTD |
| G |
CD4 |
CD4 molecule |
|
multiple interactions |
EXP |
12 |
6,898,638 |
6,929,976 |
RGD:6480464 |
CTD |
| G |
CD4 |
CD4 molecule |
|
decreases expression |
EXP |
12 |
6,898,638 |
6,929,976 |
RGD:6480464 |
CTD |
| G |
CD53 |
CD53 molecule |
|
increases expression |
EXP |
1 |
111,413,821 |
111,442,558 |
RGD:6480464 |
CTD |
| G |
CD68 |
CD68 molecule |
|
increases expression |
EXP |
17 |
7,482,805 |
7,485,429 |
RGD:6480464 |
CTD |
| G |
CD69 |
CD69 molecule |
|
increases expression |
EXP |
12 |
9,905,082 |
9,913,497 |
RGD:6480464 |
CTD |
| G |
CDA |
cytidine deaminase |
|
increases activity |
ISO |
1 |
20,915,444 |
20,945,401 |
RGD:6480464 |
CTD |
| G |
CDC42 |
cell division cycle 42 |
|
multiple interactions |
ISO |
1 |
22,379,120 |
22,419,436 |
RGD:6480464 |
CTD |
| G |
CDCA7 |
cell division cycle associated 7 |
|
decreases expression |
ISO |
2 |
174,219,561 |
174,233,718 |
RGD:6480464 |
CTD |
| G |
CDCA7 |
cell division cycle associated 7 |
|
multiple interactions |
ISO |
2 |
174,219,561 |
174,233,718 |
RGD:6480464 |
CTD |
| G |
CDH13 |
cadherin 13, H-cadherin (heart) |
|
multiple interactions |
ISO |
16 |
82,660,399 |
83,830,215 |
RGD:6480464 |
CTD |
| G |
CDH13 |
cadherin 13, H-cadherin (heart) |
|
decreases expression |
ISO |
16 |
82,660,399 |
83,830,215 |
RGD:6480464 |
CTD |
| G |
CDH13 |
cadherin 13, H-cadherin (heart) |
|
multiple interactions |
ISO |
16 |
82,660,399 |
83,830,215 |
RGD:6480464 |
CTD |
| G |
CDK1 |
cyclin-dependent kinase 1 |
|
decreases expression |
ISO |
10 |
62,538,089 |
62,554,610 |
RGD:6480464 |
CTD |
| G |
CDK2 |
cyclin-dependent kinase 2 |
|
multiple interactions |
EXP |
12 |
56,360,556 |
56,366,568 |
RGD:6480464 |
CTD |
| G |
CDK2 |
cyclin-dependent kinase 2 |
|
decreases activity |
EXP |
12 |
56,360,556 |
56,366,568 |
RGD:6480464 |
CTD |
| G |
CDK2 |
cyclin-dependent kinase 2 |
|
decreases expression |
EXP |
12 |
56,360,556 |
56,366,568 |
RGD:6480464 |
CTD |
| G |
CDK2 |
cyclin-dependent kinase 2 |
|
multiple interactions |
ISO |
12 |
56,360,556 |
56,366,568 |
RGD:6480464 |
CTD |
| G |
CDKN1A |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
|
increases expression |
ISO |
6 |
36,644,237 |
36,655,116 |
RGD:6480464 |
CTD |
| G |
CDKN1A |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
|
multiple interactions |
EXP |
6 |
36,644,237 |
36,655,116 |
RGD:6480464 |
CTD |
| G |
CDKN1A |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
|
increases expression |
ISO |
6 |
36,644,237 |
36,655,116 |
RGD:6480464 |
CTD |
| G |
CDKN1A |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
|
increases expression |
ISO |
6 |
36,644,237 |
36,655,116 |
RGD:6480464 |
CTD |
| G |
CDKN1A |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
|
multiple interactions |
ISO |
6 |
36,644,237 |
36,655,116 |
RGD:6480464 |
CTD |
| G |
CDKN3 |
cyclin-dependent kinase inhibitor 3 |
|
multiple interactions |
ISO |
14 |
54,863,673 |
54,886,936 |
RGD:6480464 |
CTD |
| G |
CDKN3 |
cyclin-dependent kinase inhibitor 3 |
|
decreases expression |
ISO |
14 |
54,863,673 |
54,886,936 |
RGD:6480464 |
CTD |
| G |
CDO1 |
cysteine dioxygenase, type I |
|
multiple interactions |
ISO |
5 |
115,140,430 |
115,152,405 |
RGD:6480464 |
CTD |
| G |
CEACAM1 |
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) |
|
increases expression |
ISO |
19 |
43,011,458 |
43,032,661 |
RGD:6480464 |
CTD |
| G |
CEACAM6 |
carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) |
|
multiple interactions |
EXP |
19 |
42,259,398 |
42,276,113 |
RGD:6480464 |
CTD |
| G |
CEBPA |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
multiple interactions |
ISO |
19 |
33,790,840 |
33,793,430 |
RGD:6480464 |
CTD |
| G |
CEBPA |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
multiple interactions |
ISO |
19 |
33,790,840 |
33,793,430 |
RGD:6480464 |
CTD |
| G |
CEBPA |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
multiple interactions |
ISO |
19 |
33,790,840 |
33,793,430 |
RGD:6480464 |
CTD |
| G |
CEBPA |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
multiple interactions |
ISO |
19 |
33,790,840 |
33,793,430 |
RGD:6480464 |
CTD |
| G |
CEBPA |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
increases expression |
ISO |
19 |
33,790,840 |
33,793,430 |
RGD:6480464 |
CTD |
| G |
CEBPA |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
increases expression |
ISO |
19 |
33,790,840 |
33,793,430 |
RGD:6480464 |
CTD |
| G |
CEBPA |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
multiple interactions |
ISO |
19 |
33,790,840 |
33,793,430 |
RGD:6480464 |
CTD |
| G |
CEBPB |
CCAAT/enhancer binding protein (C/EBP), beta |
|
multiple interactions |
ISO |
20 |
48,807,120 |
48,809,227 |
RGD:6480464 |
CTD |
| G |
CEBPB |
CCAAT/enhancer binding protein (C/EBP), beta |
|
multiple interactions |
ISO |
20 |
48,807,120 |
48,809,227 |
RGD:6480464 |
CTD |
| G |
CEBPB |
CCAAT/enhancer binding protein (C/EBP), beta |
|
multiple interactions |
ISO |
20 |
48,807,120 |
48,809,227 |
RGD:6480464 |
CTD |
| G |
CEBPB |
CCAAT/enhancer binding protein (C/EBP), beta |
|
multiple interactions |
ISO |
20 |
48,807,120 |
48,809,227 |
RGD:6480464 |
CTD |
| G |
CEBPB |
CCAAT/enhancer binding protein (C/EBP), beta |
|
increases expression |
ISO |
20 |
48,807,120 |
48,809,227 |
RGD:6480464 |
CTD |
| G |
CEBPB |
CCAAT/enhancer binding protein (C/EBP), beta |
|
multiple interactions |
ISO |
20 |
48,807,120 |
48,809,227 |
RGD:6480464 |
CTD |
| G |
CEBPB |
CCAAT/enhancer binding protein (C/EBP), beta |
|
increases expression |
ISO |
20 |
48,807,120 |
48,809,227 |
RGD:6480464 |
CTD |
| G |
CEBPD |
CCAAT/enhancer binding protein (C/EBP), delta |
|
multiple interactions |
ISO |
8 |
48,649,476 |
48,650,726 |
RGD:6480464 |
CTD |
| G |
CEBPD |
CCAAT/enhancer binding protein (C/EBP), delta |
|
increases expression |
ISO |
8 |
48,649,476 |
48,650,726 |
RGD:6480464 |
CTD |
| G |
CEBPD |
CCAAT/enhancer binding protein (C/EBP), delta |
|
multiple interactions |
ISO |
8 |
48,649,476 |
48,650,726 |
RGD:6480464 |
CTD |
| G |
CELF2 |
CUGBP, Elav-like family member 2 |
|
multiple interactions |
ISO |
10 |
11,047,259 |
11,378,674 |
RGD:6480464 |
CTD |
| G |
CELSR3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
|
decreases expression |
EXP |
3 |
48,673,896 |
48,700,348 |
RGD:6480464 |
CTD |
| G |
CES1 |
carboxylesterase 1 |
|
increases expression |
EXP |
16 |
55,836,763 |
55,867,075 |
RGD:6480464 |
CTD |
| G |
CES1 |
carboxylesterase 1 |
|
decreases expression |
ISO |
16 |
55,836,763 |
55,867,075 |
RGD:6480464 |
CTD |
| G |
CES2 |
carboxylesterase 2 |
|
affects expression |
ISO |
16 |
66,968,347 |
66,978,999 |
RGD:6480464 |
CTD |
| G |
CES2 |
carboxylesterase 2 |
|
increases expression |
EXP |
16 |
66,968,347 |
66,978,999 |
RGD:6480464 |
CTD |
| G |
CES2 |
carboxylesterase 2 |
|
multiple interactions |
ISO |
16 |
66,968,347 |
66,978,999 |
RGD:6480464 |
CTD |
| G |
CES2 |
carboxylesterase 2 |
|
decreases expression |
ISO |
16 |
66,968,347 |
66,978,999 |
RGD:6480464 |
CTD |
| G |
CES2 |
carboxylesterase 2 |
|
increases expression |
ISO |
16 |
66,968,347 |
66,978,999 |
RGD:6480464 |
CTD |
| G |
CES3 |
carboxylesterase 3 |
|
decreases expression |
ISO |
16 |
66,995,132 |
67,009,052 |
RGD:6480464 |
CTD |
| G |
CFD |
complement factor D (adipsin) |
|
decreases expression |
ISO |
19 |
859,665 |
863,624 |
RGD:6480464 |
CTD |
| G |
CFLAR |
CASP8 and FADD-like apoptosis regulator |
|
increases expression |
EXP |
2 |
201,980,877 |
202,037,411 |
RGD:6480464 |
CTD |
| G |
CFLAR |
CASP8 and FADD-like apoptosis regulator |
|
multiple interactions |
EXP |
2 |
201,980,877 |
202,037,411 |
RGD:6480464 |
CTD |
| G |
CHI3L1 |
chitinase 3-like 1 (cartilage glycoprotein-39) |
|
decreases expression |
EXP |
1 |
203,148,059 |
203,155,922 |
RGD:6480464 |
CTD |
| G |
CHID1 |
chitinase domain containing 1 |
|
multiple interactions |
EXP |
11 |
867,859 |
915,058 |
RGD:6480464 |
CTD |
| G |
CHID1 |
chitinase domain containing 1 |
|
increases expression |
EXP |
11 |
867,859 |
915,058 |
RGD:6480464 |
CTD |
| G |
CHRND |
cholinergic receptor, nicotinic, delta (muscle) |
|
increases expression |
ISO |
2 |
233,390,870 |
233,401,375 |
RGD:6480464 |
CTD |
| G |
CHRND |
cholinergic receptor, nicotinic, delta (muscle) |
|
multiple interactions |
ISO |
2 |
233,390,870 |
233,401,375 |
RGD:6480464 |
CTD |
| G |
CHUK |
conserved helix-loop-helix ubiquitous kinase |
|
multiple interactions |
EXP |
10 |
101,948,124 |
101,989,344 |
RGD:6480464 |
CTD |
| G |
CIB2 |
calcium and integrin binding family member 2 |
|
multiple interactions |
ISO |
15 |
78,396,991 |
78,423,878 |
RGD:6480464 |
CTD |
| G |
CIB2 |
calcium and integrin binding family member 2 |
|
decreases expression |
ISO |
15 |
78,396,991 |
78,423,878 |
RGD:6480464 |
CTD |
| G |
CIDEA |
cell death-inducing DFFA-like effector a |
|
increases expression |
ISO |
18 |
12,254,318 |
12,277,594 |
RGD:6480464 |
CTD |
| G |
CIDEA |
cell death-inducing DFFA-like effector a |
|
multiple interactions |
ISO |
18 |
12,254,318 |
12,277,594 |
RGD:6480464 |
CTD |
| G |
CIRBP |
cold inducible RNA binding protein |
|
decreases expression |
ISO |
19 |
1,269,267 |
1,274,809 |
RGD:6480464 |
CTD |
| G |
CITED2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
|
multiple interactions |
ISO |
6 |
139,693,392 |
139,695,787 |
RGD:6480464 |
CTD |
| G |
CKB |
creatine kinase, brain |
|
increases expression |
ISO |
14 |
103,985,995 |
103,989,196 |
RGD:6480464 |
CTD |
| G |
CLCN4 |
chloride channel, voltage-sensitive 4 |
|
decreases expression |
ISO |
X |
10,124,985 |
10,205,700 |
RGD:6480464 |
CTD |
| G |
CLEC3B |
C-type lectin domain family 3, member B |
|
multiple interactions |
ISO |
3 |
45,067,759 |
45,077,563 |
RGD:6480464 |
CTD |
| G |
CLIC3 |
chloride intracellular channel 3 |
|
multiple interactions |
EXP |
9 |
139,889,060 |
139,891,024 |
RGD:6480464 |
CTD |
| G |
CLN6 |
ceroid-lipofuscinosis, neuronal 6, late infantile, variant |
|
decreases expression |
ISO |
15 |
68,499,330 |
68,522,080 |
RGD:6480464 |
CTD |
| G |
CLN6 |
ceroid-lipofuscinosis, neuronal 6, late infantile, variant |
|
multiple interactions |
ISO |
15 |
68,499,330 |
68,522,080 |
RGD:6480464 |
CTD |
| G |
CLU |
clusterin |
|
decreases expression |
ISO |
8 |
27,454,434 |
27,472,328 |
RGD:6480464 |
CTD |
| G |
CLU |
clusterin |
|
multiple interactions |
ISO |
8 |
27,454,434 |
27,472,328 |
RGD:6480464 |
CTD |
| G |
CNKSR1 |
connector enhancer of kinase suppressor of Ras 1 |
|
increases expression |
ISO |
1 |
26,503,981 |
26,516,375 |
RGD:6480464 |
CTD |
| G |
CNKSR1 |
connector enhancer of kinase suppressor of Ras 1 |
|
multiple interactions |
ISO |
1 |
26,503,981 |
26,516,375 |
RGD:6480464 |
CTD |
| G |
CNN2 |
calponin 2 |
|
multiple interactions |
ISO |
19 |
1,026,298 |
1,039,064 |
RGD:6480464 |
CTD |
| G |
CNTN1 |
contactin 1 |
|
decreases expression |
ISO |
12 |
41,086,244 |
41,466,214 |
RGD:6480464 |
CTD |
| G |
CNTN1 |
contactin 1 |
|
multiple interactions |
ISO |
12 |
41,086,244 |
41,466,214 |
RGD:6480464 |
CTD |
| G |
COL11A1 |
collagen, type XI, alpha 1 |
|
multiple interactions |
ISO |
1 |
103,342,023 |
103,574,052 |
RGD:6480464 |
CTD |
| G |
COL15A1 |
collagen, type XV, alpha 1 |
|
multiple interactions |
EXP |
9 |
101,706,138 |
101,833,068 |
RGD:6480464 |
CTD |
| G |
COL15A1 |
collagen, type XV, alpha 1 |
|
multiple interactions |
ISO |
9 |
101,706,138 |
101,833,068 |
RGD:6480464 |
CTD |
| G |
COL15A1 |
collagen, type XV, alpha 1 |
|
decreases expression |
ISO |
9 |
101,706,138 |
101,833,068 |
RGD:6480464 |
CTD |
| G |
COL1A1 |
collagen, type I, alpha 1 |
|
decreases expression |
ISO |
17 |
48,261,457 |
48,279,000 |
RGD:6480464 |
CTD |
| G |
COL2A1 |
collagen, type II, alpha 1 |
|
multiple interactions |
EXP |
12 |
48,366,748 |
48,398,285 |
RGD:6480464 |
CTD |
| G |
COL2A1 |
collagen, type II, alpha 1 |
|
affects expression |
ISO |
12 |
48,366,748 |
48,398,285 |
RGD:6480464 |
CTD |
| G |
COL3A1 |
collagen, type III, alpha 1 |
|
decreases expression |
ISO |
2 |
189,839,099 |
189,877,472 |
RGD:6480464 |
CTD |
| G |
COL3A1 |
collagen, type III, alpha 1 |
|
multiple interactions |
ISO |
2 |
189,839,099 |
189,877,472 |
RGD:6480464 |
CTD |
| G |
COL4A1 |
collagen, type IV, alpha 1 |
|
multiple interactions |
ISO |
13 |
110,801,310 |
110,959,496 |
RGD:6480464 |
CTD |
| G |
COL4A6 |
collagen, type IV, alpha 6 |
|
multiple interactions |
EXP |
X |
107,398,837 |
107,682,704 |
RGD:6480464 |
CTD |
| G |
COL5A1 |
collagen, type V, alpha 1 |
|
decreases expression |
ISO |
9 |
137,533,652 |
137,736,689 |
RGD:6480464 |
CTD |
| G |
COL5A1 |
collagen, type V, alpha 1 |
|
multiple interactions |
ISO |
9 |
137,533,652 |
137,736,689 |
RGD:6480464 |
CTD |
| G |
COL5A2 |
collagen, type V, alpha 2 |
|
decreases expression |
ISO |
2 |
189,896,641 |
190,044,605 |
RGD:6480464 |
CTD |
| G |
COL5A2 |
collagen, type V, alpha 2 |
|
multiple interactions |
ISO |
2 |
189,896,641 |
190,044,605 |
RGD:6480464 |
CTD |
| G |
COL5A3 |
collagen, type V, alpha 3 |
|
multiple interactions |
ISO |
19 |
10,070,237 |
10,121,147 |
RGD:6480464 |
CTD |
| G |
COL5A3 |
collagen, type V, alpha 3 |
|
decreases expression |
ISO |
19 |
10,070,237 |
10,121,147 |
RGD:6480464 |
CTD |
| G |
COL6A3 |
collagen, type VI, alpha 3 |
|
multiple interactions |
ISO |
2 |
238,232,655 |
238,322,850 |
RGD:6480464 |
CTD |
| G |
COL6A3 |
collagen, type VI, alpha 3 |
|
decreases expression |
ISO |
2 |
238,232,655 |
238,322,850 |
RGD:6480464 |
CTD |
| G |
COL6A3 |
collagen, type VI, alpha 3 |
|
multiple interactions |
ISO |
2 |
238,232,655 |
238,322,850 |
RGD:6480464 |
CTD |
| G |
COL7A1 |
collagen, type VII, alpha 1 |
|
multiple interactions |
EXP |
3 |
48,601,506 |
48,632,593 |
RGD:6480464 |
CTD |
| G |
COL9A1 |
collagen, type IX, alpha 1 |
|
affects expression |
ISO |
6 |
70,925,743 |
71,012,786 |
RGD:6480464 |
CTD |
| G |
COMT |
catechol-O-methyltransferase |
|
increases expression |
ISO |
22 |
19,929,263 |
19,957,498 |
RGD:6480464 |
CTD |
| G |
COMT |
catechol-O-methyltransferase |
|
multiple interactions |
ISO |
22 |
19,929,263 |
19,957,498 |
RGD:6480464 |
CTD |
| G |
COPB2 |
coatomer protein complex, subunit beta 2 (beta prime) |
|
multiple interactions |
ISO |
3 |
139,076,433 |
139,108,522 |
RGD:6480464 |
CTD |
| G |
COPB2 |
coatomer protein complex, subunit beta 2 (beta prime) |
|
decreases expression |
ISO |
3 |
139,076,433 |
139,108,522 |
RGD:6480464 |
CTD |
| G |
CP |
ceruloplasmin (ferroxidase) |
|
multiple interactions |
ISO |
3 |
148,880,197 |
148,939,832 |
RGD:6480464 |
CTD |
| G |
CP |
ceruloplasmin (ferroxidase) |
|
increases expression |
ISO |
3 |
148,880,197 |
148,939,832 |
RGD:6480464 |
CTD |
| G |
CP |
ceruloplasmin (ferroxidase) |
|
multiple interactions |
ISO |
3 |
148,880,197 |
148,939,832 |
RGD:6480464 |
CTD |
| G |
CPA1 |
carboxypeptidase A1 (pancreatic) |
|
decreases expression |
ISO |
7 |
130,020,290 |
130,027,949 |
RGD:6480464 |
CTD |
| G |
CPA1 |
carboxypeptidase A1 (pancreatic) |
|
multiple interactions |
ISO |
7 |
130,020,290 |
130,027,949 |
RGD:6480464 |
CTD |
| G |
CPE |
carboxypeptidase E |
|
decreases expression |
ISO |
4 |
166,300,097 |
166,419,482 |
RGD:6480464 |
CTD |
| G |
CPE |
carboxypeptidase E |
|
multiple interactions |
ISO |
4 |
166,300,097 |
166,419,482 |
RGD:6480464 |
CTD |
| G |
CPN1 |
carboxypeptidase N, polypeptide 1 |
|
increases expression |
ISO |
10 |
101,802,065 |
101,841,642 |
RGD:6480464 |
CTD |
| G |
CPS1 |
carbamoyl-phosphate synthase 1, mitochondrial |
|
increases expression |
ISO |
2 |
211,342,406 |
211,543,831 |
RGD:6480464 |
CTD |
| G |
CPS1 |
carbamoyl-phosphate synthase 1, mitochondrial |
|
increases expression |
ISO |
2 |
211,342,406 |
211,543,831 |
RGD:6480464 |
CTD |
| G |
CRABP2 |
cellular retinoic acid binding protein 2 |
|
decreases expression |
ISO |
1 |
156,669,398 |
156,675,608 |
RGD:6480464 |
CTD |
| G |
CREB1 |
cAMP responsive element binding protein 1 |
|
increases phosphorylation |
EXP |
2 |
208,394,616 |
208,470,284 |
RGD:6480464 |
CTD |
| G |
CRH |
corticotropin releasing hormone |
|
increases expression |
ISO |
8 |
67,088,612 |
67,090,846 |
RGD:6480464 |
CTD |
| G |
CRISP1 |
cysteine-rich secretory protein 1 |
|
decreases expression |
ISO |
6 |
49,801,970 |
49,844,809 |
RGD:6480464 |
CTD |
| G |
CRISP1 |
cysteine-rich secretory protein 1 |
|
multiple interactions |
ISO |
6 |
49,801,970 |
49,844,809 |
RGD:6480464 |
CTD |
| G |
CRKL |
v-crk sarcoma virus CT10 oncogene homolog (avian)-like |
|
multiple interactions |
ISO |
22 |
21,271,714 |
21,308,037 |
RGD:6480464 |
CTD |
| G |
CRYAB |
crystallin, alpha B |
|
increases expression |
EXP |
11 |
111,779,350 |
111,782,473 |
RGD:6480464 |
CTD |
| G |
CRYAB |
crystallin, alpha B |
|
multiple interactions |
EXP |
11 |
111,779,350 |
111,782,473 |
RGD:6480464 |
CTD |
| G |
CSF1 |
colony stimulating factor 1 (macrophage) |
|
multiple interactions |
ISO |
1 |
110,453,233 |
110,473,616 |
RGD:6480464 |
CTD |
| G |
CSF1R |
colony stimulating factor 1 receptor |
|
increases expression |
EXP |
5 |
149,432,854 |
149,492,935 |
RGD:6480464 |
CTD |
| G |
CSF2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
EXP |
5 |
131,409,485 |
131,411,863 |
RGD:6480464 |
CTD |
| G |
CSF2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
EXP |
5 |
131,409,485 |
131,411,863 |
RGD:6480464 |
CTD |
| G |
CSF2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
EXP |
5 |
131,409,485 |
131,411,863 |
RGD:6480464 |
CTD |
| G |
CSF2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
EXP |
5 |
131,409,485 |
131,411,863 |
RGD:6480464 |
CTD |
| G |
CSF2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
5 |
131,409,485 |
131,411,863 |
RGD:6480464 |
CTD |
| G |
CSF3 |
colony stimulating factor 3 (granulocyte) |
|
increases expression |
EXP |
17 |
38,171,614 |
38,174,066 |
RGD:6480464 |
CTD |
| G |
CSRP3 |
cysteine and glycine-rich protein 3 (cardiac LIM protein) |
|
increases expression |
ISO |
11 |
19,203,577 |
19,232,118 |
RGD:6480464 |
CTD |
| G |
CSRP3 |
cysteine and glycine-rich protein 3 (cardiac LIM protein) |
|
multiple interactions |
ISO |
11 |
19,203,577 |
19,232,118 |
RGD:6480464 |
CTD |
| G |
CST6 |
cystatin E/M |
|
multiple interactions |
EXP |
11 |
65,779,462 |
65,780,976 |
RGD:6480464 |
CTD |
| G |
CTNNB1 |
catenin (cadherin-associated protein), beta 1, 88kDa |
|
decreases expression |
ISO |
3 |
41,240,942 |
41,281,939 |
RGD:6480464 |
CTD |
| G |
CTNNB1 |
catenin (cadherin-associated protein), beta 1, 88kDa |
|
decreases expression |
ISO |
3 |
41,240,942 |
41,281,939 |
RGD:6480464 |
CTD |
| G |
CTSL1 |
cathepsin L1 |
|
increases expression |
ISO |
9 |
90,340,974 |
90,346,384 |
RGD:6480464 |
CTD |
| G |
CTSL1 |
cathepsin L1 |
|
increases expression |
ISO |
9 |
90,340,974 |
90,346,384 |
RGD:6480464 |
CTD |
| G |
CTSL1 |
cathepsin L1 |
|
multiple interactions |
ISO |
9 |
90,340,974 |
90,346,384 |
RGD:6480464 |
CTD |
| G |
CX3CL1 |
chemokine (C-X3-C motif) ligand 1 |
|
multiple interactions |
ISO |
16 |
57,406,414 |
57,418,956 |
RGD:6480464 |
CTD |
| G |
CXCL1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
multiple interactions |
ISO |
4 |
74,735,109 |
74,737,019 |
RGD:6480464 |
CTD |
| G |
CXCL1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
multiple interactions |
ISO |
4 |
74,735,109 |
74,737,019 |
RGD:6480464 |
CTD |
| G |
CXCL1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
multiple interactions |
ISO |
4 |
74,735,109 |
74,737,019 |
RGD:6480464 |
CTD |
| G |
CXCL1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
multiple interactions |
ISO |
4 |
74,735,109 |
74,737,019 |
RGD:6480464 |
CTD |
| G |
CXCL12 |
chemokine (C-X-C motif) ligand 12 |
|
multiple interactions |
ISO |
10 |
44,865,605 |
44,880,545 |
RGD:6480464 |
CTD |
| G |
CXCL2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
ISO |
4 |
74,962,752 |
74,964,997 |
RGD:6480464 |
CTD |
| G |
CXCL2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
ISO |
4 |
74,962,752 |
74,964,997 |
RGD:6480464 |
CTD |
| G |
CXCL2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
ISO |
4 |
74,962,752 |
74,964,997 |
RGD:6480464 |
CTD |
| G |
CXCL2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
ISO |
4 |
74,962,752 |
74,964,997 |
RGD:6480464 |
CTD |
| G |
CXCL5 |
chemokine (C-X-C motif) ligand 5 |
|
multiple interactions |
ISO |
4 |
74,861,359 |
74,864,416 |
RGD:6480464 |
CTD |
| G |
CXCR4 |
chemokine (C-X-C motif) receptor 4 |
|
increases expression |
EXP |
2 |
136,871,919 |
136,875,725 |
RGD:6480464 |
CTD |
| G |
CXCR4 |
chemokine (C-X-C motif) receptor 4 |
|
multiple interactions |
EXP |
2 |
136,871,919 |
136,875,725 |
RGD:6480464 |
CTD |
| G |
CXCR4 |
chemokine (C-X-C motif) receptor 4 |
|
increases expression |
EXP |
2 |
136,871,919 |
136,875,725 |
RGD:6480464 |
CTD |
| G |
CXCR7 |
chemokine (C-X-C motif) receptor 7 |
|
decreases expression |
ISO |
2 |
237,478,380 |
237,490,997 |
RGD:6480464 |
CTD |
| G |
CYB5R3 |
cytochrome b5 reductase 3 |
|
decreases expression |
ISO |
22 |
43,013,846 |
43,045,405 |
RGD:6480464 |
CTD |
| G |
CYBB |
cytochrome b-245, beta polypeptide |
|
multiple interactions |
EXP |
X |
37,639,270 |
37,672,714 |
RGD:6480464 |
CTD |
| G |
CYCS |
cytochrome c, somatic |
|
multiple interactions |
EXP |
7 |
25,158,270 |
25,164,980 |
RGD:6480464 |
CTD |
| G |
CYP19A1 |
cytochrome P450, family 19, subfamily A, polypeptide 1 |
|
multiple interactions |
EXP |
15 |
51,500,254 |
51,630,795 |
RGD:6480464 |
CTD |
| G |
CYP19A1 |
cytochrome P450, family 19, subfamily A, polypeptide 1 |
|
increases expression |
EXP |
15 |
51,500,254 |
51,630,795 |
RGD:6480464 |
CTD |
| G |
CYP19A1 |
cytochrome P450, family 19, subfamily A, polypeptide 1 |
|
increases activity |
EXP |
15 |
51,500,254 |
51,630,795 |
RGD:6480464 |
CTD |
| G |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions |
EXP |
15 |
75,011,883 |
75,017,877 |
RGD:6480464 |
CTD |
| G |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions |
EXP |
15 |
75,011,883 |
75,017,877 |
RGD:6480464 |
CTD |
| G |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions |
EXP |
15 |
75,011,883 |
75,017,877 |
RGD:6480464 |
CTD |
| G |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
decreases activity |
EXP |
15 |
75,011,883 |
75,017,877 |
RGD:6480464 |
CTD |
| G |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
decreases expression |
EXP |
15 |
75,011,883 |
75,017,877 |
RGD:6480464 |
CTD |
| G |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions |
ISO |
15 |
75,011,883 |
75,017,877 |
RGD:6480464 |
CTD |
| G |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions |
ISO |
15 |
75,011,883 |
75,017,877 |
RGD:6480464 |
CTD |
| G |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions |
ISO |
15 |
75,011,883 |
75,017,877 |
RGD:6480464 |
CTD |
| G |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions |
ISO |
15 |
75,011,883 |
75,017,877 |
RGD:6480464 |
CTD |
| G |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
increases activity |
ISO |
15 |
75,011,883 |
75,017,877 |
RGD:6480464 |
CTD |
| G |
CYP1A2 |
cytochrome P450, family 1, subfamily A, polypeptide 2 |
|
multiple interactions |
EXP |
15 |
75,041,184 |
75,048,941 |
RGD:6480464 |
CTD |
| G |
CYP1A2 |
cytochrome P450, family 1, subfamily A, polypeptide 2 |
|
decreases expression |
EXP |
15 |
75,041,184 |
75,048,941 |
RGD:6480464 |
CTD |
| G |
CYP1A2 |
cytochrome P450, family 1, subfamily A, polypeptide 2 |
|
decreases activity |
EXP |
15 |
75,041,184 |
75,048,941 |
RGD:6480464 |
CTD |
| G |
CYP1A2 |
cytochrome P450, family 1, subfamily A, polypeptide 2 |
|
affects expression |
ISO |
15 |
75,041,184 |
75,048,941 |
RGD:6480464 |
CTD |
| G |
CYP1A2 |
cytochrome P450, family 1, subfamily A, polypeptide 2 |
|
multiple interactions |
ISO |
15 |
75,041,184 |
75,048,941 |
RGD:6480464 |
CTD |
| G |
CYP1A2 |
cytochrome P450, family 1, subfamily A, polypeptide 2 |
|
increases expression |
ISO |
15 |
75,041,184 |
75,048,941 |
RGD:6480464 |
CTD |
| G |
CYP1B1 |
cytochrome P450, family 1, subfamily B, polypeptide 1 |
|
multiple interactions |
ISO |
2 |
38,294,746 |
38,303,323 |
RGD:6480464 |
CTD |
| G |
CYP1B1 |
cytochrome P450, family 1, subfamily B, polypeptide 1 |
|
multiple interactions |
ISO |
2 |
38,294,746 |
38,303,323 |
RGD:6480464 |
CTD |
| G |
CYP24A1 |
cytochrome P450, family 24, subfamily A, polypeptide 1 |
|
affects activity |
ISO |
20 |
52,769,988 |
52,790,516 |
RGD:6480464 |
CTD |
| G |
CYP24A1 |
cytochrome P450, family 24, subfamily A, polypeptide 1 |
|
affects expression |
ISO |
20 |
52,769,988 |
52,790,516 |
RGD:6480464 |
CTD |
| G |
CYP24A1 |
cytochrome P450, family 24, subfamily A, polypeptide 1 |
|
increases expression |
ISO |
20 |
52,769,988 |
52,790,516 |
RGD:6480464 |
CTD |
| G |
CYP27A1 |
cytochrome P450, family 27, subfamily A, polypeptide 1 |
|
multiple interactions |
EXP |
2 |
219,646,472 |
219,680,016 |
RGD:6480464 |
CTD |
| G |
CYP27A1 |
cytochrome P450, family 27, subfamily A, polypeptide 1 |
|
increases expression |
EXP |
2 |
219,646,472 |
219,680,016 |
RGD:6480464 |
CTD |
| G |
CYP27B1 |
cytochrome P450, family 27, subfamily B, polypeptide 1 |
|
affects expression |
ISO |
12 |
58,156,117 |
58,160,976 |
RGD:6480464 |
CTD |
| G |
CYP27B1 |
cytochrome P450, family 27, subfamily B, polypeptide 1 |
|
affects activity |
ISO |
12 |
58,156,117 |
58,160,976 |
RGD:6480464 |
CTD |
| G |
CYP2A6 |
cytochrome P450, family 2, subfamily A, polypeptide 6 |
|
multiple interactions |
EXP |
19 |
41,349,443 |
41,356,352 |
RGD:6480464 |
CTD |
| G |
CYP2A6 |
cytochrome P450, family 2, subfamily A, polypeptide 6 |
|
increases activity |
EXP |
19 |
41,349,443 |
41,356,352 |
RGD:6480464 |
CTD |
| G |
CYP2A6 |
cytochrome P450, family 2, subfamily A, polypeptide 6 |
|
increases expression |
EXP |
19 |
41,349,443 |
41,356,352 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
affects expression |
ISO |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases expression |
ISO |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
multiple interactions |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
multiple interactions |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases expression |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2B6 |
cytochrome P450, family 2, subfamily B, polypeptide 6 |
|
increases expression |
EXP |
19 |
41,497,204 |
41,524,301 |
RGD:6480464 |
CTD |
| G |
CYP2C8 |
cytochrome P450, family 2, subfamily C, polypeptide 8 |
|
affects binding |
EXP |
10 |
96,796,529 |
96,829,254 |
RGD:6480464 |
CTD |
| G |
CYP2C8 |
cytochrome P450, family 2, subfamily C, polypeptide 8 |
|
increases expression |
EXP |
10 |
96,796,529 |
96,829,254 |
RGD:6480464 |
CTD |
| G |
CYP2C9 |
cytochrome P450, family 2, subfamily C, polypeptide 9 |
|
multiple interactions |
EXP |
10 |
96,698,415 |
96,749,148 |
RGD:6480464 |
CTD |
| G |
CYP2C9 |
cytochrome P450, family 2, subfamily C, polypeptide 9 |
|
increases expression |
EXP |
10 |
96,698,415 |
96,749,148 |
RGD:6480464 |
CTD |
| G |
CYP2E1 |
cytochrome P450, family 2, subfamily E, polypeptide 1 |
|
increases expression |
ISO |
10 |
135,340,867 |
135,352,620 |
RGD:6480464 |
CTD |
| G |
CYP2E1 |
cytochrome P450, family 2, subfamily E, polypeptide 1 |
|
decreases expression |
ISO |
10 |
135,340,867 |
135,352,620 |
RGD:6480464 |
CTD |
| G |
CYP2E1 |
cytochrome P450, family 2, subfamily E, polypeptide 1 |
|
increases expression |
ISO |
10 |
135,340,867 |
135,352,620 |
RGD:6480464 |
CTD |
| G |
CYP3A |
cytochrome P450, subfamily IIA (niphedipine oxidase) |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
CYP3A |
cytochrome P450, subfamily IIA (niphedipine oxidase) |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
increases expression |
ISO |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
affects expression |
ISO |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
increases expression |
ISO |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
affects metabolic processing |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
multiple interactions |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
multiple interactions |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
multiple interactions |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
increases activity |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
increases expression |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
multiple interactions |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
increases expression |
EXP |
7 |
99,354,583 |
99,381,811 |
RGD:6480464 |
CTD |
| G |
CYP3A5 |
cytochrome P450, family 3, subfamily A, polypeptide 5 |
|
increases expression |
EXP |
7 |
99,245,813 |
99,277,621 |
RGD:6480464 |
CTD |
| G |
CYP3A5 |
cytochrome P450, family 3, subfamily A, polypeptide 5 |
|
decreases expression |
ISO |
7 |
99,245,813 |
99,277,621 |
RGD:6480464 |
CTD |
| G |
CYP3A7 |
cytochrome P450, family 3, subfamily A, polypeptide 7 |
|
increases expression |
ISO |
7 |
99,302,660 |
99,332,819 |
RGD:6480464 |
CTD |
| G |
CYP4Z1 |
cytochrome P450, family 4, subfamily Z, polypeptide 1 |
|
increases expression |
EXP |
1 |
47,533,160 |
47,583,992 |
RGD:6480464 |
CTD |
| G |
CYP4Z1 |
cytochrome P450, family 4, subfamily Z, polypeptide 1 |
|
multiple interactions |
EXP |
1 |
47,533,160 |
47,583,992 |
RGD:6480464 |
CTD |
| G |
CYP51A1 |
cytochrome P450, family 51, subfamily A, polypeptide 1 |
|
decreases expression |
ISO |
7 |
91,741,463 |
91,764,059 |
RGD:6480464 |
CTD |
| G |
CYP51A1 |
cytochrome P450, family 51, subfamily A, polypeptide 1 |
|
affects expression |
ISO |
7 |
91,741,463 |
91,764,059 |
RGD:6480464 |
CTD |
| G |
CYP7A1 |
cytochrome P450, family 7, subfamily A, polypeptide 1 |
|
increases expression |
ISO |
8 |
59,402,737 |
59,412,720 |
RGD:6480464 |
CTD |
| G |
DBH |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
multiple interactions |
ISO |
9 |
136,501,485 |
136,524,466 |
RGD:6480464 |
CTD |
| G |
DBH |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
increases expression |
ISO |
9 |
136,501,485 |
136,524,466 |
RGD:6480464 |
CTD |
| G |
DBH |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
multiple interactions |
ISO |
9 |
136,501,485 |
136,524,466 |
RGD:6480464 |
CTD |
| G |
DBH |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
decreases expression |
ISO |
9 |
136,501,485 |
136,524,466 |
RGD:6480464 |
CTD |
| G |
DBP |
D site of albumin promoter (albumin D-box) binding protein |
|
decreases expression |
ISO |
19 |
49,133,817 |
49,140,639 |
RGD:6480464 |
CTD |
| G |
DBP |
D site of albumin promoter (albumin D-box) binding protein |
|
increases expression |
ISO |
19 |
49,133,817 |
49,140,639 |
RGD:6480464 |
CTD |
| G |
DCN |
decorin |
|
multiple interactions |
ISO |
12 |
91,539,035 |
91,576,806 |
RGD:6480464 |
CTD |
| G |
DDIT4 |
DNA-damage-inducible transcript 4 |
|
increases expression |
ISO |
10 |
74,033,677 |
74,035,797 |
RGD:6480464 |
CTD |
| G |
DDIT4 |
DNA-damage-inducible transcript 4 |
|
multiple interactions |
ISO |
10 |
74,033,677 |
74,035,797 |
RGD:6480464 |
CTD |
| G |
DDIT4 |
DNA-damage-inducible transcript 4 |
|
increases expression |
ISO |
10 |
74,033,677 |
74,035,797 |
RGD:6480464 |
CTD |
| G |
DECR1 |
2,4-dienoyl CoA reductase 1, mitochondrial |
|
increases expression |
ISO |
8 |
91,013,580 |
91,064,227 |
RGD:6480464 |
CTD |
| G |
DEGS1 |
delta(4)-desaturase, sphingolipid 1 |
|
decreases expression |
ISO |
1 |
224,370,910 |
224,381,143 |
RGD:6480464 |
CTD |
| G |
DEGS1 |
delta(4)-desaturase, sphingolipid 1 |
|
multiple interactions |
ISO |
1 |
224,370,910 |
224,381,143 |
RGD:6480464 |
CTD |
| G |
DFNA5 |
deafness, autosomal dominant 5 |
|
increases expression |
EXP |
7 |
24,737,974 |
24,797,639 |
RGD:6480464 |
CTD |
| G |
DGAT1 |
diacylglycerol O-acyltransferase 1 |
|
multiple interactions |
ISO |
8 |
145,538,247 |
145,550,567 |
RGD:6480464 |
CTD |
| G |
DGAT2 |
diacylglycerol O-acyltransferase 2 |
|
increases expression |
ISO |
11 |
75,479,778 |
75,512,581 |
RGD:6480464 |
CTD |
| G |
DGAT2 |
diacylglycerol O-acyltransferase 2 |
|
multiple interactions |
ISO |
11 |
75,479,778 |
75,512,581 |
RGD:6480464 |
CTD |
| G |
DIABLO |
diablo, IAP-binding mitochondrial protein |
|
affects localization |
EXP |
12 |
122,692,209 |
122,712,068 |
RGD:6480464 |
CTD |
| G |
DIABLO |
diablo, IAP-binding mitochondrial protein |
|
multiple interactions |
EXP |
12 |
122,692,209 |
122,712,068 |
RGD:6480464 |
CTD |
| G |
DIO3 |
deiodinase, iodothyronine, type III |
|
decreases activity |
EXP |
14 |
102,027,688 |
102,029,789 |
RGD:6480464 |
CTD |
| G |
DNAJA1 |
DnaJ (Hsp40) homolog, subfamily A, member 1 |
|
increases expression |
ISO |
9 |
33,025,209 |
33,039,062 |
RGD:6480464 |
CTD |
| G |
DNAJB9 |
DnaJ (Hsp40) homolog, subfamily B, member 9 |
|
multiple interactions |
ISO |
7 |
108,210,189 |
108,215,294 |
RGD:6480464 |
CTD |
| G |
DNAJB9 |
DnaJ (Hsp40) homolog, subfamily B, member 9 |
|
increases expression |
ISO |
7 |
108,210,189 |
108,215,294 |
RGD:6480464 |
CTD |
| G |
DUSP1 |
dual specificity phosphatase 1 |
|
increases expression |
EXP |
5 |
172,195,093 |
172,198,203 |
RGD:6480464 |
CTD |
| G |
DUSP1 |
dual specificity phosphatase 1 |
|
multiple interactions |
ISO |
5 |
172,195,093 |
172,198,203 |
RGD:6480464 |
CTD |
| G |
DUSP28 |
dual specificity phosphatase 28 |
|
increases expression |
ISO |
2 |
241,499,471 |
241,503,431 |
RGD:6480464 |
CTD |
| G |
EDN1 |
endothelin 1 |
|
multiple interactions |
ISO |
6 |
12,290,529 |
12,297,427 |
RGD:6480464 |
CTD |
| G |
EDN1 |
endothelin 1 |
|
decreases expression |
EXP |
6 |
12,290,529 |
12,297,427 |
RGD:6480464 |
CTD |
| G |
EDN1 |
endothelin 1 |
|
multiple interactions |
ISO |
6 |
12,290,529 |
12,297,427 |
RGD:6480464 |
CTD |
| G |
EDNRB |
endothelin receptor type B |
|
multiple interactions |
ISO |
13 13 |
78,469,616 78,513,393 |
78,549,664 78,549,674 |
RGD:6480464 |
CTD |
| G |
EEF1A2 |
eukaryotic translation elongation factor 1 alpha 2 |
|
increases expression |
EXP |
20 |
62,119,365 |
62,130,668 |
RGD:6480464 |
CTD |
| G |
EGF |
epidermal growth factor |
|
multiple interactions |
ISO |
4 |
110,834,040 |
110,934,118 |
RGD:6480464 |
CTD |
| G |
EGF |
epidermal growth factor |
|
multiple interactions |
ISO |
4 |
110,834,040 |
110,934,118 |
RGD:6480464 |
CTD |
| G |
EGF |
epidermal growth factor |
|
multiple interactions |
EXP |
4 |
110,834,040 |
110,934,118 |
RGD:6480464 |
CTD |
| G |
EGF |
epidermal growth factor |
|
multiple interactions |
EXP |
4 |
110,834,040 |
110,934,118 |
RGD:6480464 |
CTD |
| G |
EGF |
epidermal growth factor |
|
multiple interactions |
ISO |
4 |
110,834,040 |
110,934,118 |
RGD:6480464 |
CTD |
| G |
EGF |
epidermal growth factor |
|
multiple interactions |
ISO |
4 |
110,834,040 |
110,934,118 |
RGD:6480464 |
CTD |
| G |
EGFR |
epidermal growth factor receptor |
|
multiple interactions |
EXP |
7 |
55,086,725 |
55,275,031 |
RGD:6480464 |
CTD |
| G |
EGFR |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
7 |
55,086,725 |
55,275,031 |
RGD:6480464 |
CTD |
| G |
EGR1 |
early growth response 1 |
|
multiple interactions |
ISO |
5 |
137,801,181 |
137,805,004 |
RGD:6480464 |
CTD |
| G |
EIF4EBP1 |
eukaryotic translation initiation factor 4E binding protein 1 |
|
increases expression |
ISO |
8 |
37,888,020 |
37,917,883 |
RGD:6480464 |
CTD |
| G |
EIF4EBP1 |
eukaryotic translation initiation factor 4E binding protein 1 |
|
multiple interactions |
ISO |
8 |
37,888,020 |
37,917,883 |
RGD:6480464 |
CTD |
| G |
EIF4G3 |
eukaryotic translation initiation factor 4 gamma, 3 |
|
increases expression |
ISO |
1 |
21,132,785 |
21,503,381 |
RGD:6480464 |
CTD |
| G |
EIF4G3 |
eukaryotic translation initiation factor 4 gamma, 3 |
|
multiple interactions |
ISO |
1 |
21,132,785 |
21,503,381 |
RGD:6480464 |
CTD |
| G |
ELOVL3 |
ELOVL fatty acid elongase 3 |
|
multiple interactions |
ISO |
10 |
103,986,143 |
103,989,346 |
RGD:6480464 |
CTD |
| G |
ELOVL6 |
ELOVL fatty acid elongase 6 |
|
multiple interactions |
ISO |
4 |
110,970,229 |
111,119,820 |
RGD:6480464 |
CTD |
| G |
EMB |
embigin |
|
multiple interactions |
ISO |
5 |
49,692,031 |
49,737,234 |
RGD:6480464 |
CTD |
| G |
EMP1 |
epithelial membrane protein 1 |
|
multiple interactions |
ISO |
12 |
13,349,602 |
13,369,708 |
RGD:6480464 |
CTD |
| G |
EMP2 |
epithelial membrane protein 2 |
|
multiple interactions |
EXP |
16 |
10,622,279 |
10,674,539 |
RGD:6480464 |
CTD |
| G |
ENDOD1 |
endonuclease domain containing 1 |
|
decreases expression |
EXP |
11 |
94,822,974 |
94,865,815 |
RGD:6480464 |
CTD |
| G |
ENPP2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
|
multiple interactions |
ISO |
8 |
120,569,317 |
120,651,106 |
RGD:6480464 |
CTD |
| G |
EP300 |
E1A binding protein p300 |
|
multiple interactions |
ISO |
22 |
41,488,614 |
41,576,081 |
RGD:6480464 |
CTD |
| G |
EPHA7 |
EPH receptor A7 |
|
multiple interactions |
ISO |
6 |
93,949,738 |
94,129,300 |
RGD:6480464 |
CTD |
| G |
EPHA7 |
EPH receptor A7 |
|
decreases expression |
ISO |
6 |
93,949,738 |
94,129,300 |
RGD:6480464 |
CTD |
| G |
EPHX2 |
epoxide hydrolase 2, cytoplasmic |
|
multiple interactions |
ISO |
8 |
27,348,519 |
27,402,439 |
RGD:6480464 |
CTD |
| G |
EPHX2 |
epoxide hydrolase 2, cytoplasmic |
|
increases expression |
ISO |
8 |
27,348,519 |
27,402,439 |
RGD:6480464 |
CTD |
| G |
ERBB4 |
v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) |
|
increases expression |
EXP |
2 |
212,240,442 |
213,403,352 |
RGD:6480464 |
CTD |
| G |
EREG |
epiregulin |
|
increases expression |
EXP |
4 |
75,230,860 |
75,254,477 |
RGD:6480464 |
CTD |
| G |
ERP29 |
endoplasmic reticulum protein 29 |
|
decreases expression |
ISO |
12 |
112,451,152 |
112,461,024 |
RGD:6480464 |
CTD |
| G |
ERRFI1 |
ERBB receptor feedback inhibitor 1 |
|
increases expression |
ISO |
1 |
8,071,779 |
8,086,393 |
RGD:6480464 |
CTD |
| G |
ESPL1 |
extra spindle pole bodies homolog 1 (S. cerevisiae) |
|
multiple interactions |
ISO |
12 |
53,662,083 |
53,687,427 |
RGD:6480464 |
CTD |
| G |
ESPL1 |
extra spindle pole bodies homolog 1 (S. cerevisiae) |
|
decreases expression |
ISO |
12 |
53,662,083 |
53,687,427 |
RGD:6480464 |
CTD |
| G |
ESR1 |
estrogen receptor 1 |
|
decreases expression |
EXP |
6 |
152,011,631 |
152,424,409 |
RGD:6480464 |
CTD |
| G |
ETS1 |
v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) |
|
decreases expression |
ISO |
11 |
128,328,656 |
128,457,453 |
RGD:6480464 |
CTD |
| G |
ETS2 |
v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) |
|
increases expression |
EXP |
21 |
40,177,231 |
40,196,879 |
RGD:6480464 |
CTD |
| G |
EVL |
Enah/Vasp-like |
|
multiple interactions |
ISO |
14 |
100,531,751 |
100,610,573 |
RGD:6480464 |
CTD |
| G |
EVL |
Enah/Vasp-like |
|
decreases expression |
ISO |
14 |
100,531,751 |
100,610,573 |
RGD:6480464 |
CTD |
| G |
EXOC2 |
exocyst complex component 2 |
|
decreases expression |
ISO |
6 |
485,138 |
693,141 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II (thrombin) |
|
multiple interactions |
EXP |
11 |
46,740,743 |
46,761,056 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II (thrombin) |
|
multiple interactions |
ISO |
11 |
46,740,743 |
46,761,056 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II (thrombin) |
|
affects expression |
ISO |
11 |
46,740,743 |
46,761,056 |
RGD:6480464 |
CTD |
| G |
F2R |
coagulation factor II (thrombin) receptor |
|
increases expression |
EXP |
5 |
76,011,868 |
76,031,595 |
RGD:6480464 |
CTD |
| G |
F2R |
coagulation factor II (thrombin) receptor |
|
affects expression |
ISO |
5 |
76,011,868 |
76,031,595 |
RGD:6480464 |
CTD |
| G |
F2R |
coagulation factor II (thrombin) receptor |
|
increases expression |
ISO |
5 |
76,011,868 |
76,031,595 |
RGD:6480464 |
CTD |
| G |
F2R |
coagulation factor II (thrombin) receptor |
|
multiple interactions |
ISO |
5 |
76,011,868 |
76,031,595 |
RGD:6480464 |
CTD |
| G |
F3 |
coagulation factor III (thromboplastin, tissue factor) |
|
multiple interactions |
EXP |
1 |
94,994,732 |
95,007,413 |
RGD:6480464 |
CTD |
| G |
F3 |
coagulation factor III (thromboplastin, tissue factor) |
|
multiple interactions |
ISO |
1 |
94,994,732 |
95,007,413 |
RGD:6480464 |
CTD |
| G |
F3 |
coagulation factor III (thromboplastin, tissue factor) |
|
multiple interactions |
ISO |
1 |
94,994,732 |
95,007,413 |
RGD:6480464 |
CTD |
| G |
FABP1 |
fatty acid binding protein 1, liver |
|
decreases expression |
ISO |
2 |
88,422,501 |
88,427,650 |
RGD:6480464 |
CTD |
| G |
FABP4 |
fatty acid binding protein 4, adipocyte |
|
multiple interactions |
EXP |
8 |
82,390,732 |
82,395,473 |
RGD:6480464 |
CTD |
| G |
FABP4 |
fatty acid binding protein 4, adipocyte |
|
multiple interactions |
ISO |
8 |
82,390,732 |
82,395,473 |
RGD:6480464 |
CTD |
| G |
FABP4 |
fatty acid binding protein 4, adipocyte |
|
multiple interactions |
ISO |
8 |
82,390,732 |
82,395,473 |
RGD:6480464 |
CTD |
| G |
FABP4 |
fatty acid binding protein 4, adipocyte |
|
multiple interactions |
ISO |
8 |
82,390,732 |
82,395,473 |
RGD:6480464 |
CTD |
| G |
FADS1 |
fatty acid desaturase 1 |
|
decreases expression |
ISO |
11 |
61,567,097 |
61,584,529 |
RGD:6480464 |
CTD |
| G |
FAH |
fumarylacetoacetate hydrolase (fumarylacetoacetase) |
|
increases expression |
ISO |
15 |
80,445,233 |
80,478,924 |
RGD:6480464 |
CTD |
| G |
FAH |
fumarylacetoacetate hydrolase (fumarylacetoacetase) |
|
multiple interactions |
ISO |
15 |
80,445,233 |
80,478,924 |
RGD:6480464 |
CTD |
| G |
FAM208A |
family with sequence similarity 208, member A |
|
increases expression |
ISO |
3 |
56,654,160 |
56,717,135 |
RGD:6480464 |
CTD |
| G |
FAM216A |
family with sequence similarity 216, member A |
|
decreases expression |
EXP |
12 |
110,906,232 |
110,928,192 |
RGD:6480464 |
CTD |
| G |
FAM65B |
family with sequence similarity 65, member B |
|
increases expression |
EXP |
6 |
24,804,513 |
24,911,195 |
RGD:6480464 |
CTD |
| G |
FAS |
Fas (TNF receptor superfamily, member 6) |
|
increases expression |
EXP |
10 |
90,750,288 |
90,775,542 |
RGD:6480464 |
CTD |
| G |
FAS |
Fas (TNF receptor superfamily, member 6) |
|
multiple interactions |
EXP |
10 |
90,750,288 |
90,775,542 |
RGD:6480464 |
CTD |
| G |
FAS |
Fas (TNF receptor superfamily, member 6) |
|
multiple interactions |
ISO |
10 |
90,750,288 |
90,775,542 |
RGD:6480464 |
CTD |
| G |
FAS |
Fas (TNF receptor superfamily, member 6) |
|
decreases expression |
ISO |
10 |
90,750,288 |
90,775,542 |
RGD:6480464 |
CTD |
| G |
FASLG |
Fas ligand (TNF superfamily, member 6) |
|
decreases expression |
EXP |
1 |
172,628,185 |
172,636,013 |
RGD:6480464 |
CTD |
| G |
FASLG |
Fas ligand (TNF superfamily, member 6) |
|
decreases secretion |
EXP |
1 |
172,628,185 |
172,636,013 |
RGD:6480464 |
CTD |
| G |
FASLG |
Fas ligand (TNF superfamily, member 6) |
|
decreases expression |
ISO |
1 |
172,628,185 |
172,636,013 |
RGD:6480464 |
CTD |
| G |
FASN |
fatty acid synthase |
|
increases expression |
ISO |
17 |
80,036,214 |
80,056,106 |
RGD:6480464 |
CTD |
| G |
FBN2 |
fibrillin 2 |
|
multiple interactions |
ISO |
5 |
127,593,601 |
127,873,735 |
RGD:6480464 |
CTD |
| G |
FBP2 |
fructose-1,6-bisphosphatase 2 |
|
decreases expression |
ISO |
9 |
97,321,002 |
97,356,075 |
RGD:6480464 |
CTD |
| G |
FBP2 |
fructose-1,6-bisphosphatase 2 |
|
multiple interactions |
ISO |
9 |
97,321,002 |
97,356,075 |
RGD:6480464 |
CTD |
| G |
FBXO32 |
F-box protein 32 |
|
multiple interactions |
ISO |
8 |
124,510,127 |
124,553,493 |
RGD:6480464 |
CTD |
| G |
FBXO32 |
F-box protein 32 |
|
increases expression |
ISO |
8 |
124,510,127 |
124,553,493 |
RGD:6480464 |
CTD |
| G |
FBXO32 |
F-box protein 32 |
|
increases expression |
ISO |
8 |
124,510,127 |
124,553,493 |
RGD:6480464 |
CTD |
| G |
FBXO32 |
F-box protein 32 |
|
multiple interactions |
ISO |
8 |
124,510,127 |
124,553,493 |
RGD:6480464 |
CTD |
| G |
FDFT1 |
farnesyl-diphosphate farnesyltransferase 1 |
|
increases expression |
ISO |
8 |
11,660,190 |
11,696,818 |
RGD:6480464 |
CTD |
| G |
FDPS |
farnesyl diphosphate synthase |
|
multiple interactions |
ISO |
1 |
155,278,539 |
155,290,457 |
RGD:6480464 |
CTD |
| G |
FDX1 |
ferredoxin 1 |
|
multiple interactions |
ISO |
11 |
110,300,661 |
110,335,608 |
RGD:6480464 |
CTD |
| G |
FDX1 |
ferredoxin 1 |
|
decreases expression |
ISO |
11 |
110,300,661 |
110,335,608 |
RGD:6480464 |
CTD |
| G |
FDX1 |
ferredoxin 1 |
|
multiple interactions |
ISO |
11 |
110,300,661 |
110,335,608 |
RGD:6480464 |
CTD |
| G |
FGB |
fibrinogen beta chain |
|
decreases expression |
ISO |
4 |
155,484,132 |
155,493,915 |
RGD:6480464 |
CTD |
| G |
FGF2 |
fibroblast growth factor 2 (basic) |
|
multiple interactions |
ISO |
4 |
123,747,863 |
123,819,390 |
RGD:6480464 |
CTD |
| G |
FGF7 |
fibroblast growth factor 7 |
|
multiple interactions |
ISO |
15 |
49,715,375 |
49,779,523 |
RGD:6480464 |
CTD |
| G |
FGFR2 |
fibroblast growth factor receptor 2 |
|
multiple interactions |
ISO |
10 |
123,237,844 |
123,357,972 |
RGD:6480464 |
CTD |
| G |
FGFR2 |
fibroblast growth factor receptor 2 |
|
decreases expression |
ISO |
10 |
123,237,844 |
123,357,972 |
RGD:6480464 |
CTD |
| G |
FGFR2 |
fibroblast growth factor receptor 2 |
|
multiple interactions |
ISO |
10 |
123,237,844 |
123,357,972 |
RGD:6480464 |
CTD |
| G |
FGFR3 |
fibroblast growth factor receptor 3 |
|
decreases response to substance |
ISO |
4 |
1,795,039 |
1,810,599 |
RGD:6480464 |
CTD |
| G |
FHL1 |
four and a half LIM domains 1 |
|
increases expression |
EXP |
X |
135,228,861 |
135,293,518 |
RGD:6480464 |
CTD |
| G |
FIGF |
c-fos induced growth factor (vascular endothelial growth factor D) |
|
multiple interactions |
ISO |
X |
15,363,713 |
15,402,535 |
RGD:6480464 |
CTD |
| G |
FKBP4 |
FK506 binding protein 4, 59kDa |
|
increases expression |
ISO |
12 |
2,904,108 |
2,914,589 |
RGD:6480464 |
CTD |
| G |
FKBP4 |
FK506 binding protein 4, 59kDa |
|
multiple interactions |
ISO |
12 |
2,904,108 |
2,914,589 |
RGD:6480464 |
CTD |
| G |
FKBP5 |
FK506 binding protein 5 |
|
increases expression |
EXP |
6 |
35,541,362 |
35,696,360 |
RGD:6480464 |
CTD |
| G |
FKBP5 |
FK506 binding protein 5 |
|
multiple interactions |
EXP |
6 |
35,541,362 |
35,696,360 |
RGD:6480464 |
CTD |
| G |
FKBP5 |
FK506 binding protein 5 |
|
multiple interactions |
ISO |
6 |
35,541,362 |
35,696,360 |
RGD:6480464 |
CTD |
| G |
FKBP5 |
FK506 binding protein 5 |
|
increases expression |
ISO |
6 |
35,541,362 |
35,696,360 |
RGD:6480464 |
CTD |
| G |
FKBP5 |
FK506 binding protein 5 |
|
multiple interactions |
ISO |
6 |
35,541,362 |
35,696,360 |
RGD:6480464 |
CTD |
| G |
FKBP5 |
FK506 binding protein 5 |
|
multiple interactions |
EXP |
6 |
35,541,362 |
35,696,360 |
RGD:6480464 |
CTD |
| G |
FKBP5 |
FK506 binding protein 5 |
|
increases expression |
EXP |
6 |
35,541,362 |
35,696,360 |
RGD:6480464 |
CTD |
| G |
FLOT1 |
flotillin 1 |
|
multiple interactions |
EXP |
6 |
30,695,511 |
30,710,453 |
RGD:6480464 |
CTD |
| G |
FMO1 |
flavin containing monooxygenase 1 |
|
affects expression |
ISO |
1 |
171,217,663 |
171,255,113 |
RGD:6480464 |
CTD |
| G |
FMO1 |
flavin containing monooxygenase 1 |
|
multiple interactions |
ISO |
1 |
171,217,663 |
171,255,113 |
RGD:6480464 |
CTD |
| G |
FMO3 |
flavin containing monooxygenase 3 |
|
multiple interactions |
ISO |
1 |
171,060,018 |
171,086,959 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
multiple interactions |
ISO |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
decreases expression |
ISO |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
decreases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOSL2 |
FOS-like antigen 2 |
|
increases expression |
ISO |
2 |
28,615,779 |
28,637,516 |
RGD:6480464 |
CTD |
| G |
FOXG1B |
forkhead box G1B |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
FOXG1B |
forkhead box G1B |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
FOXO1 |
forkhead box O1 |
|
increases expression |
ISO |
13 |
41,129,801 |
41,240,734 |
RGD:6480464 |
CTD |
| G |
FOXO1 |
forkhead box O1 |
|
increases expression |
ISO |
13 |
41,129,801 |
41,240,734 |
RGD:6480464 |
CTD |
| G |
FOXO1 |
forkhead box O1 |
|
multiple interactions |
ISO |
13 |
41,129,801 |
41,240,734 |
RGD:6480464 |
CTD |
| G |
FOXQ1 |
forkhead box Q1 |
|
multiple interactions |
ISO |
6 |
1,312,675 |
1,314,993 |
RGD:6480464 |
CTD |
| G |
FPR1 |
formyl peptide receptor 1 |
|
increases expression |
EXP |
19 |
52,249,023 |
52,255,150 |
RGD:6480464 |
CTD |
| G |
FPR1 |
formyl peptide receptor 1 |
|
multiple interactions |
EXP |
19 |
52,249,023 |
52,255,150 |
RGD:6480464 |
CTD |
| G |
FSCN1 |
fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) |
|
multiple interactions |
ISO |
7 |
5,632,436 |
5,646,287 |
RGD:6480464 |
CTD |
| G |
HAO1 |
hydroxyacid oxidase (glycolate oxidase) 1 |
|
multiple interactions |
ISO |
20 |
7,863,631 |
7,921,093 |
RGD:6480464 |
CTD |
| G |
HAS2 |
hyaluronan synthase 2 |
|
decreases expression |
EXP |
8 |
122,625,271 |
122,653,630 |
RGD:6480464 |
CTD |
| G |
HBEGF |
heparin-binding EGF-like growth factor |
|
decreases expression |
ISO |
5 |
139,712,428 |
139,726,188 |
RGD:6480464 |
CTD |
| G |
HDAC1 |
histone deacetylase 1 |
|
multiple interactions |
ISO |
1 |
32,757,708 |
32,799,224 |
RGD:6480464 |
CTD |
| G |
HDAC4 |
histone deacetylase 4 |
|
increases expression |
EXP |
2 |
239,969,864 |
240,322,643 |
RGD:6480464 |
CTD |
| G |
HDC |
histidine decarboxylase |
|
multiple interactions |
ISO |
15 |
50,534,144 |
50,558,162 |
RGD:6480464 |
CTD |
| G |
HDC |
histidine decarboxylase |
|
multiple interactions |
ISO |
15 |
50,534,144 |
50,558,162 |
RGD:6480464 |
CTD |
| G |
HDC |
histidine decarboxylase |
|
decreases activity |
ISO |
15 |
50,534,144 |
50,558,162 |
RGD:6480464 |
CTD |
| G |
HDC |
histidine decarboxylase |
|
decreases expression |
ISO |
15 |
50,534,144 |
50,558,162 |
RGD:6480464 |
CTD |
| G |
HES1 |
hairy and enhancer of split 1, (Drosophila) |
|
decreases expression |
EXP |
3 |
193,853,931 |
193,856,401 |
RGD:6480464 |
CTD |
| G |
HIBADH |
3-hydroxyisobutyrate dehydrogenase |
|
increases expression |
ISO |
7 |
27,565,059 |
27,702,620 |
RGD:6480464 |
CTD |
| G |
HIST4H4 |
histone cluster 4, H4 |
|
increases acetylation |
EXP |
12 |
14,923,654 |
14,924,065 |
RGD:6480464 |
CTD |
| G |
HIST4H4 |
histone cluster 4, H4 |
|
multiple interactions |
EXP |
12 |
14,923,654 |
14,924,065 |
RGD:6480464 |
CTD |
| G |
HK2 |
hexokinase 2 |
|
multiple interactions |
ISO |
2 |
75,059,782 |
75,120,481 |
RGD:6480464 |
CTD |
| G |
HK2 |
hexokinase 2 |
|
decreases expression |
ISO |
2 |
75,059,782 |
75,120,481 |
RGD:6480464 |
CTD |
| G |
HLA-DMB |
major histocompatibility complex, class II, DM beta |
|
decreases expression |
EXP |
6 |
32,902,406 |
32,908,847 |
RGD:6480464 |
CTD |
| G |
HLA-DPB1 |
major histocompatibility complex, class II, DP beta 1 |
|
increases expression |
EXP |
6 |
33,043,703 |
33,057,473 |
RGD:6480464 |
CTD |
| G |
HLA-DQA1 |
major histocompatibility complex, class II, DQ alpha 1 |
|
increases expression |
EXP |
6 |
32,605,183 |
32,611,429 |
RGD:6480464 |
CTD |
| G |
HLA-DQB1 |
major histocompatibility complex, class II, DQ beta 1 |
|
affects expression |
EXP |
6 |
32,627,241 |
32,634,466 |
RGD:6480464 |
CTD |
| G |
HLA-DRA |
major histocompatibility complex, class II, DR alpha |
|
increases expression |
EXP |
6 |
32,407,619 |
32,412,823 |
RGD:6480464 |
CTD |
| G |
HMGB2 |
high mobility group box 2 |
|
decreases expression |
ISO |
4 |
174,252,527 |
174,255,595 |
RGD:6480464 |
CTD |
| G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
multiple interactions |
ISO |
5 |
74,632,993 |
74,657,926 |
RGD:6480464 |
CTD |
| G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
increases expression |
ISO |
5 |
74,632,993 |
74,657,926 |
RGD:6480464 |
CTD |
| G |
HMGCS1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) |
|
decreases expression |
EXP |
5 |
43,287,572 |
43,313,614 |
RGD:6480464 |
CTD |
| G |
HMGCS1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) |
|
increases expression |
ISO |
5 |
43,287,572 |
43,313,614 |
RGD:6480464 |
CTD |
| G |
IL12B |
interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40) |
|
multiple interactions |
ISO |
5 |
158,741,791 |
158,757,481 |
RGD:6480464 |
CTD |
| G |
IL12B |
interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40) |
|
multiple interactions |
ISO |
5 |
158,741,791 |
158,757,481 |
RGD:6480464 |
CTD |
| G |
IL12RB1 |
interleukin 12 receptor, beta 1 |
|
decreases expression |
EXP |
19 |
18,170,371 |
18,197,697 |
RGD:6480464 |
CTD |
| G |
IL12RB2 |
interleukin 12 receptor, beta 2 |
|
decreases expression |
EXP |
1 |
67,773,047 |
67,862,583 |
RGD:6480464 |
CTD |
| G |
IL13 |
interleukin 13 |
|
multiple interactions |
EXP |
5 |
131,993,865 |
131,996,801 |
RGD:6480464 |
CTD |
| G |
IL13 |
interleukin 13 |
|
decreases expression |
ISO |
5 |
131,993,865 |
131,996,801 |
RGD:6480464 |
CTD |
| G |
IL13RA1 |
interleukin 13 receptor, alpha 1 |
|
increases expression |
ISO |
X |
117,861,559 |
117,928,496 |
RGD:6480464 |
CTD |
| G |
IL15 |
interleukin 15 |
|
increases expression |
EXP |
4 |
142,557,749 |
142,655,140 |
RGD:6480464 |
CTD |
| G |
IL15 |
interleukin 15 |
|
decreases expression |
ISO |
4 |
142,557,749 |
142,655,140 |
RGD:6480464 |
CTD |
| G |
IL1A |
interleukin 1, alpha |
|
multiple interactions |
ISO |
2 |
113,531,492 |
113,542,971 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
EXP |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
EXP |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
EXP |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
EXP |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
EXP |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
EXP |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
EXP |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
ISO |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INSR |
insulin receptor |
|
multiple interactions |
ISO |
19 |
7,112,266 |
7,294,011 |
RGD:6480464 |
CTD |
| G |
IRS1 |
insulin receptor substrate 1 |
|
multiple interactions |
ISO |
2 |
227,596,033 |
227,663,506 |
RGD:6480464 |
CTD |
| G |
ITGAM |
integrin, alpha M (complement component 3 receptor 3 subunit) |
|
multiple interactions |
EXP |
16 |
31,271,288 |
31,344,213 |
RGD:6480464 |
CTD |
| G |
ITSN1 |
intersectin 1 (SH3 domain protein) |
|
decreases expression |
ISO |
21 |
35,014,784 |
35,261,609 |
RGD:6480464 |
CTD |
| G |
ITSN1 |
intersectin 1 (SH3 domain protein) |
|
multiple interactions |
ISO |
21 |
35,014,784 |
35,261,609 |
RGD:6480464 |
CTD |
| G |
JAG1 |
jagged 1 |
|
multiple interactions |
ISO |
20 |
10,618,332 |
10,654,694 |
RGD:6480464 |
CTD |
| G |
JAM3 |
junctional adhesion molecule 3 |
|
increases expression |
EXP |
11 |
133,938,820 |
134,021,652 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
decreases expression |
ISO |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
KCNA2 |
potassium voltage-gated channel, shaker-related subfamily, member 2 |
|
multiple interactions |
ISO |
1 |
111,136,202 |
111,174,096 |
RGD:6480464 |
CTD |
| G |
KCNA5 |
potassium voltage-gated channel, shaker-related subfamily, member 5 |
|
increases expression |
ISO |
12 |
5,153,085 |
5,155,954 |
RGD:6480464 |
CTD |
| G |
KCNA5 |
potassium voltage-gated channel, shaker-related subfamily, member 5 |
|
multiple interactions |
ISO |
12 |
5,153,085 |
5,155,954 |
RGD:6480464 |
CTD |
| G |
KCNAB1 |
potassium voltage-gated channel, shaker-related subfamily, beta member 1 |
|
decreases expression |
ISO |
3 |
155,838,337 |
156,256,927 |
RGD:6480464 |
CTD |
| G |
KCNAB1 |
potassium voltage-gated channel, shaker-related subfamily, beta member 1 |
|
multiple interactions |
ISO |
3 |
155,838,337 |
156,256,927 |
RGD:6480464 |
CTD |
| G |
KCNB1 |
potassium voltage-gated channel, Shab-related subfamily, member 1 |
|
multiple interactions |
ISO |
20 |
47,988,505 |
48,099,181 |
RGD:6480464 |
CTD |
| G |
KCNK1 |
potassium channel, subfamily K, member 1 |
|
increases expression |
ISO |
1 |
233,749,750 |
233,808,258 |
RGD:6480464 |
CTD |
| G |
KCNMA1 |
potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
|
multiple interactions |
ISO |
10 |
78,629,359 |
79,397,577 |
RGD:6480464 |
CTD |
| G |
KCNN4 |
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
|
decreases expression |
ISO |
19 |
44,270,685 |
44,285,409 |
RGD:6480464 |
CTD |
| G |
KCNN4 |
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
|
multiple interactions |
ISO |
19 |
44,270,685 |
44,285,409 |
RGD:6480464 |
CTD |
| G |
KCTD12 |
potassium channel tetramerisation domain containing 12 |
|
multiple interactions |
EXP |
13 |
77,454,304 |
77,460,540 |
RGD:6480464 |
CTD |
| G |
KIF1A |
kinesin family member 1A |
|
multiple interactions |
ISO |
2 |
241,653,181 |
241,759,725 |
RGD:6480464 |
CTD |
| G |
KIF1A |
kinesin family member 1A |
|
decreases expression |
ISO |
2 |
241,653,181 |
241,759,725 |
RGD:6480464 |
CTD |
| G |
KIT |
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog |
|
decreases expression |
ISO |
4 |
55,524,095 |
55,606,881 |
RGD:6480464 |
CTD |
| G |
KITLG |
KIT ligand |
|
multiple interactions |
ISO |
12 |
88,886,570 |
88,974,250 |
RGD:6480464 |
CTD |
| G |
KLF4 |
Kruppel-like factor 4 (gut) |
|
multiple interactions |
ISO |
9 |
110,247,133 |
110,252,047 |
RGD:6480464 |
CTD |
| G |
MAPK8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
EXP |
10 |
49,609,687 |
49,643,183 |
RGD:6480464 |
CTD |
| G |
MAPK8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
10 |
49,609,687 |
49,643,183 |
RGD:6480464 |
CTD |
| G |
MAPK8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
10 |
49,609,687 |
49,643,183 |
RGD:6480464 |
CTD |
| G |
MAPK8 |
mitogen-activated protein kinase 8 |
|
affects phosphorylation |
ISO |
10 |
49,609,687 |
49,643,183 |
RGD:6480464 |
CTD |
| G |
MARCKS |
myristoylated alanine-rich protein kinase C substrate |
|
multiple interactions |
ISO |
6 |
114,178,527 |
114,184,652 |
RGD:6480464 |
CTD |
| G |
MBL2 |
mannose-binding lectin (protein C) 2, soluble |
|
decreases expression |
ISO |
10 |
54,525,140 |
54,531,460 |
RGD:6480464 |
CTD |
| G |
MBL2 |
mannose-binding lectin (protein C) 2, soluble |
|
multiple interactions |
ISO |
10 |
54,525,140 |
54,531,460 |
RGD:6480464 |
CTD |
| G |
MBNL1 |
muscleblind-like splicing regulator 1 |
|
increases expression |
ISO |
3 |
151,985,829 |
152,183,569 |
RGD:6480464 |
CTD |
| G |
MBNL1 |
muscleblind-like splicing regulator 1 |
|
multiple interactions |
ISO |
3 |
151,985,829 |
152,183,569 |
RGD:6480464 |
CTD |
| G |
MC5R |
melanocortin 5 receptor |
|
increases expression |
ISO |
18 |
13,825,543 |
13,826,861 |
RGD:6480464 |
CTD |
| G |
MC5R |
melanocortin 5 receptor |
|
multiple interactions |
ISO |
18 |
13,825,543 |
13,826,861 |
RGD:6480464 |
CTD |
| G |
MCAM |
melanoma cell adhesion molecule |
|
decreases expression |
ISO |
11 |
119,179,234 |
119,187,840 |
RGD:6480464 |
CTD |
| G |
MCAM |
melanoma cell adhesion molecule |
|
multiple interactions |
ISO |
11 |
119,179,234 |
119,187,840 |
RGD:6480464 |
CTD |
| G |
MCL1 |
myeloid cell leukemia sequence 1 (BCL2-related) |
|
increases expression |
EXP |
1 |
150,547,027 |
150,552,214 |
RGD:6480464 |
CTD |
| G |
MCL1 |
myeloid cell leukemia sequence 1 (BCL2-related) |
|
multiple interactions |
ISO |
1 |
150,547,027 |
150,552,214 |
RGD:6480464 |
CTD |
| G |
MCL1 |
myeloid cell leukemia sequence 1 (BCL2-related) |
|
increases expression |
ISO |
1 |
150,547,027 |
150,552,214 |
RGD:6480464 |
CTD |
| G |
MCOLN2 |
mucolipin 2 |
|
decreases expression |
ISO |
1 |
85,391,266 |
85,462,796 |
RGD:6480464 |
CTD |
| G |
MCOLN2 |
mucolipin 2 |
|
multiple interactions |
ISO |
1 |
85,391,266 |
85,462,796 |
RGD:6480464 |
CTD |
| G |
ME1 |
malic enzyme 1, NADP(+)-dependent, cytosolic |
|
multiple interactions |
ISO |
6 |
83,920,108 |
84,140,938 |
RGD:6480464 |
CTD |
| G |
ME1 |
malic enzyme 1, NADP(+)-dependent, cytosolic |
|
decreases expression |
ISO |
6 |
83,920,108 |
84,140,938 |
RGD:6480464 |
CTD |
| G |
MED1 |
mediator complex subunit 1 |
|
affects response to substance |
ISO |
17 |
37,560,538 |
37,607,527 |
RGD:6480464 |
CTD |
| G |
METTL7A |
methyltransferase like 7A |
|
increases expression |
EXP |
12 |
51,318,534 |
51,326,300 |
RGD:6480464 |
CTD |
| G |
MMP9 |
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) |
|
multiple interactions |
ISO |
20 |
44,637,547 |
44,645,200 |
RGD:6480464 |
CTD |
| G |
MT-CO2 |
mitochondrially encoded cytochrome c oxidase II |
|
increases expression |
ISO |
MT |
7,586 |
8,269 |
RGD:6480464 |
CTD |
| G |
MT-CO3 |
mitochondrially encoded cytochrome c oxidase III |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
MT-COI |
mitochondrially encoded cytochrome c oxidase I |
|
increases expression |
ISO |
MT |
5,904 |
7,445 |
RGD:6480464 |
CTD |
| G |
MT1A |
metallothionein 1A |
|
multiple interactions |
ISO |
16 |
56,672,578 |
56,673,999 |
RGD:6480464 |
CTD |
| G |
MT1A |
metallothionein 1A |
|
increases expression |
ISO |
16 |
56,672,578 |
56,673,999 |
RGD:6480464 |
CTD |
| G |
MT1A |
metallothionein 1A |
|
multiple interactions |
ISO |
16 |
56,672,578 |
56,673,999 |
RGD:6480464 |
CTD |
| G |
NELFA |
negative elongation factor complex member A |
|
increases expression |
EXP |
4 |
1,984,441 |
2,010,962 |
RGD:6480464 |
CTD |
| G |
NOC2L |
nucleolar complex associated 2 homolog (S. cerevisiae) |
|
decreases expression |
EXP |
1 |
879,583 |
894,679 |
RGD:6480464 |
CTD |
| G |
NOC3L |
nucleolar complex associated 3 homolog (S. cerevisiae) |
|
increases expression |
ISO |
10 |
96,092,989 |
96,122,683 |
RGD:6480464 |
CTD |
| G |
NOL3 |
nucleolar protein 3 (apoptosis repressor with CARD domain) |
|
multiple interactions |
ISO |
16 |
67,204,405 |
67,209,643 |
RGD:6480464 |
CTD |
| G |
NOL3 |
nucleolar protein 3 (apoptosis repressor with CARD domain) |
|
increases expression |
ISO |
16 |
67,204,405 |
67,209,643 |
RGD:6480464 |
CTD |
| G |
NOP16 |
NOP16 nucleolar protein |
|
decreases expression |
EXP |
5 |
175,810,940 |
175,815,763 |
RGD:6480464 |
CTD |
| G |
NOS1 |
nitric oxide synthase 1 (neuronal) |
|
decreases expression |
ISO |
12 |
117,645,947 |
117,799,607 |
RGD:6480464 |
CTD |
| G |
NOS1 |
nitric oxide synthase 1 (neuronal) |
|
multiple interactions |
ISO |
12 |
117,645,947 |
117,799,607 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
decreases expression |
EXP |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
decreases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
decreases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
affects expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NR3C1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
multiple interactions |
ISO |
5 |
142,657,496 |
142,815,077 |
RGD:6480464 |
CTD |
| G |
NR3C1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
affects response to substance |
ISO |
5 |
142,657,496 |
142,815,077 |
RGD:6480464 |
CTD |
| G |
NR3C1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
multiple interactions |
ISO |
5 |
142,657,496 |
142,815,077 |
RGD:6480464 |
CTD |
| G |
NR3C1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
affects localization |
ISO |
5 |
142,657,496 |
142,815,077 |
RGD:6480464 |
CTD |
| G |
NR3C1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
multiple interactions |
ISO |
5 |
142,657,496 |
142,815,077 |
RGD:6480464 |
CTD |
| G |
NR3C1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
multiple interactions |
ISO |
5 |
142,657,496 |
142,815,077 |
RGD:6480464 |
CTD |
| G |
NR3C1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
increases expression |
ISO |
5 |
142,657,496 |
142,815,077 |
RGD:6480464 |
CTD |
| G |
NR3C1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
increases activity |
ISO |
5 |
142,657,496 |
142,815,077 |
RGD:6480464 |
CTD |
| G |
NR3C1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
increases expression |
ISO |
5 |
142,657,496 |
142,815,077 |
RGD:6480464 |
CTD |
| G |
NR3C1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
multiple interactions |
ISO |
5 |
142,657,496 |
142,815,077 |
RGD:6480464 |
CTD |
| G |
NR3C1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
multiple interactions |
ISO |
5 |
142,657,496 |
142,815,077 |
RGD:6480464 |
CTD |
| G |
NR3C1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
multiple interactions |
ISO |
5 |
142,657,496 |
142,815,077 |
RGD:6480464 |
CTD |
| G |
NR3C2 |
nuclear receptor subfamily 3, group C, member 2 |
|
increases expression |
EXP |
4 |
148,999,915 |
149,363,672 |
RGD:6480464 |
CTD |
| G |
NR4A1 |
nuclear receptor subfamily 4, group A, member 1 |
|
multiple interactions |
ISO |
12 |
52,416,616 |
52,453,291 |
RGD:6480464 |
CTD |
| G |
NR4A1 |
nuclear receptor subfamily 4, group A, member 1 |
|
affects localization |
ISO |
12 |
52,416,616 |
52,453,291 |
RGD:6480464 |
CTD |
| G |
NR6A1 |
nuclear receptor subfamily 6, group A, member 1 |
|
increases expression |
EXP |
9 |
127,284,703 |
127,533,576 |
RGD:6480464 |
CTD |
| G |
NRXN2 |
neurexin 2 |
|
multiple interactions |
ISO |
11 |
64,373,646 |
64,490,660 |
RGD:6480464 |
CTD |
| G |
NRXN2 |
neurexin 2 |
|
increases expression |
ISO |
11 |
64,373,646 |
64,490,660 |
RGD:6480464 |
CTD |
| G |
NUDT21 |
nudix (nucleoside diphosphate linked moiety X)-type motif 21 |
|
increases expression |
ISO |
16 |
56,463,048 |
56,485,261 |
RGD:6480464 |
CTD |
| G |
ODC1 |
ornithine decarboxylase 1 |
|
decreases expression |
ISO |
2 |
10,580,508 |
10,588,453 |
RGD:6480464 |
CTD |
| G |
ODC1 |
ornithine decarboxylase 1 |
|
increases expression |
ISO |
2 |
10,580,508 |
10,588,453 |
RGD:6480464 |
CTD |
| G |
OGN |
osteoglycin |
|
multiple interactions |
ISO |
9 |
95,146,249 |
95,166,937 |
RGD:6480464 |
CTD |
| G |
OLFM4 |
olfactomedin 4 |
|
increases expression |
EXP |
13 |
53,602,876 |
53,626,196 |
RGD:6480464 |
CTD |
| G |
OMD |
osteomodulin |
|
multiple interactions |
ISO |
9 |
95,176,527 |
95,186,836 |
RGD:6480464 |
CTD |
| G |
ONECUT1 |
one cut homeobox 1 |
|
increases expression |
ISO |
15 |
53,049,353 |
53,082,209 |
RGD:6480464 |
CTD |
| G |
ORM1 |
orosomucoid 1 |
|
multiple interactions |
ISO |
9 |
117,085,303 |
117,088,759 |
RGD:6480464 |
CTD |
| G |
ORM2 |
orosomucoid 2 |
|
multiple interactions |
ISO |
9 |
117,092,069 |
117,095,536 |
RGD:6480464 |
CTD |
| G |
PARP1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
EXP |
1 |
226,548,392 |
226,595,801 |
RGD:6480464 |
CTD |
| G |
POU5F1 |
POU class 5 homeobox 1 |
|
multiple interactions |
ISO |
6 |
31,132,114 |
31,138,451 |
RGD:6480464 |
CTD |
| G |
PPARD |
peroxisome proliferator-activated receptor delta |
|
increases expression |
EXP |
6 |
35,310,335 |
35,395,968 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
EXP |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
decreases expression |
ISO |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
increases expression |
ISO |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARGC1A |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
increases expression |
EXP |
4 |
23,793,644 |
23,891,700 |
RGD:6480464 |
CTD |
| G |
PPARGC1A |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
decreases expression |
ISO |
4 |
23,793,644 |
23,891,700 |
RGD:6480464 |
CTD |
| G |
PPARGC1A |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
multiple interactions |
ISO |
4 |
23,793,644 |
23,891,700 |
RGD:6480464 |
CTD |
| G |
PPARGC1A |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
increases expression |
ISO |
4 |
23,793,644 |
23,891,700 |
RGD:6480464 |
CTD |
| G |
PPARGC1A |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
multiple interactions |
ISO |
4 |
23,793,644 |
23,891,700 |
RGD:6480464 |
CTD |
| G |
PPAT |
phosphoribosyl pyrophosphate amidotransferase |
|
decreases expression |
EXP |
4 |
57,259,528 |
57,301,802 |
RGD:6480464 |
CTD |
| G |
PPIB |
peptidylprolyl isomerase B (cyclophilin B) |
|
increases expression |
ISO |
15 |
64,448,014 |
64,455,354 |
RGD:6480464 |
CTD |
| G |
PPIB |
peptidylprolyl isomerase B (cyclophilin B) |
|
multiple interactions |
ISO |
15 |
64,448,014 |
64,455,354 |
RGD:6480464 |
CTD |
| G |
PPP2R5A |
protein phosphatase 2, regulatory subunit B', alpha |
|
decreases expression |
ISO |
1 |
212,458,879 |
212,535,205 |
RGD:6480464 |
CTD |
| G |
PPP3CB |
protein phosphatase 3, catalytic subunit, beta isozyme |
|
decreases expression |
EXP |
10 |
75,196,563 |
75,255,782 |
RGD:6480464 |
CTD |
| G |
PRIM2 |
primase, DNA, polypeptide 2 (58kDa) |
|
decreases expression |
ISO |
6 |
57,182,415 |
57,512,702 |
RGD:6480464 |
CTD |
| G |
PRIM2 |
primase, DNA, polypeptide 2 (58kDa) |
|
multiple interactions |
ISO |
6 |
57,182,415 |
57,512,702 |
RGD:6480464 |
CTD |
| G |
PRKACB |
protein kinase, cAMP-dependent, catalytic, beta |
|
decreases phosphorylation |
ISO |
1 |
84,543,745 |
84,704,181 |
RGD:6480464 |
CTD |
| G |
PRKACB |
protein kinase, cAMP-dependent, catalytic, beta |
|
multiple interactions |
ISO |
1 |
84,543,745 |
84,704,181 |
RGD:6480464 |
CTD |
| G |
RASA3 |
RAS p21 protein activator 3 |
|
multiple interactions |
ISO |
13 |
114,747,194 |
114,898,095 |
RGD:6480464 |
CTD |
| G |
RORA |
RAR-related orphan receptor A |
|
multiple interactions |
ISO |
15 |
60,780,483 |
61,521,502 |
RGD:6480464 |
CTD |
| G |
RXRA |
retinoid X receptor, alpha |
|
increases expression |
EXP |
9 |
137,218,316 |
137,332,431 |
RGD:6480464 |
CTD |
| G |
S100A8 |
S100 calcium binding protein A8 |
|
increases expression |
EXP |
1 |
153,362,508 |
153,363,664 |
RGD:6480464 |
CTD |
| G |
S100A9 |
S100 calcium binding protein A9 |
|
increases expression |
EXP |
1 |
153,330,330 |
153,333,503 |
RGD:6480464 |
CTD |
| G |
S100A9 |
S100 calcium binding protein A9 |
|
decreases expression |
ISO |
1 |
153,330,330 |
153,333,503 |
RGD:6480464 |
CTD |
| G |
S100A9 |
S100 calcium binding protein A9 |
|
increases expression |
ISO |
1 |
153,330,330 |
153,333,503 |
RGD:6480464 |
CTD |
| G |
S100A9 |
S100 calcium binding protein A9 |
|
multiple interactions |
ISO |
1 |
153,330,330 |
153,333,503 |
RGD:6480464 |
CTD |
| G |
SCARB1 |
scavenger receptor class B, member 1 |
|
decreases expression |
ISO |
12 |
125,262,174 |
125,348,519 |
RGD:6480464 |
CTD |
| G |
SCD |
stearoyl-CoA desaturase (delta-9-desaturase) |
|
decreases expression |
ISO |
10 |
102,106,772 |
102,124,588 |
RGD:6480464 |
CTD |
| G |
SCD |
stearoyl-CoA desaturase (delta-9-desaturase) |
|
affects expression |
ISO |
10 |
102,106,772 |
102,124,588 |
RGD:6480464 |
CTD |
| G |
SCEL |
sciellin |
|
increases expression |
EXP |
13 |
78,109,809 |
78,219,398 |
RGD:6480464 |
CTD |
| G |
SCN8A |
sodium channel, voltage gated, type VIII, alpha subunit |
|
decreases expression |
ISO |
12 |
51,985,020 |
52,206,648 |
RGD:6480464 |
CTD |
| G |
SCN8A |
sodium channel, voltage gated, type VIII, alpha subunit |
|
multiple interactions |
ISO |
12 |
51,985,020 |
52,206,648 |
RGD:6480464 |
CTD |
| G |
SCNN1A |
sodium channel, non-voltage-gated 1 alpha subunit |
|
increases expression |
ISO |
12 |
6,456,009 |
6,486,523 |
RGD:6480464 |
CTD |
| G |
SCNN1B |
sodium channel, non-voltage-gated 1, beta subunit |
|
multiple interactions |
EXP |
16 |
23,313,591 |
23,392,620 |
RGD:6480464 |
CTD |
| G |
SCNN1B |
sodium channel, non-voltage-gated 1, beta subunit |
|
increases expression |
EXP |
16 |
23,313,591 |
23,392,620 |
RGD:6480464 |
CTD |
| G |
SCNN1B |
sodium channel, non-voltage-gated 1, beta subunit |
|
increases expression |
ISO |
16 |
23,313,591 |
23,392,620 |
RGD:6480464 |
CTD |
| G |
SCNN1B |
sodium channel, non-voltage-gated 1, beta subunit |
|
increases expression |
ISO |
16 |
23,313,591 |
23,392,620 |
RGD:6480464 |
CTD |
| G |
SCNN1G |
sodium channel, non-voltage-gated 1, gamma subunit |
|
multiple interactions |
EXP |
16 |
23,194,040 |
23,228,200 |
RGD:6480464 |
CTD |
| G |
SCNN1G |
sodium channel, non-voltage-gated 1, gamma subunit |
|
increases expression |
EXP |
16 |
23,194,040 |
23,228,200 |
RGD:6480464 |
CTD |
| G |
SCNN1G |
sodium channel, non-voltage-gated 1, gamma subunit |
|
increases expression |
ISO |
16 |
23,194,040 |
23,228,200 |
RGD:6480464 |
CTD |
| G |
SDC1 |
syndecan 1 |
|
decreases expression |
EXP |
2 |
20,400,558 |
20,425,194 |
RGD:6480464 |
CTD |
| G |
SDC2 |
syndecan 2 |
|
multiple interactions |
ISO |
8 |
97,505,882 |
97,624,037 |
RGD:6480464 |
CTD |
| G |
SDC4 |
syndecan 4 |
|
increases expression |
ISO |
20 |
43,953,928 |
43,977,064 |
RGD:6480464 |
CTD |
| G |
SDC4 |
syndecan 4 |
|
multiple interactions |
ISO |
20 |
43,953,928 |
43,977,064 |
RGD:6480464 |
CTD |
| G |
SDCBP |
syndecan binding protein (syntenin) |
|
increases expression |
EXP |
8 |
59,465,728 |
59,495,419 |
RGD:6480464 |
CTD |
| G |
SEPHS2 |
selenophosphate synthetase 2 |
|
increases expression |
ISO |
16 |
30,454,952 |
30,457,224 |
RGD:6480464 |
CTD |
| G |
SEPHS2 |
selenophosphate synthetase 2 |
|
multiple interactions |
ISO |
16 |
30,454,952 |
30,457,224 |
RGD:6480464 |
CTD |
| G |
SEPP1 |
selenoprotein P, plasma, 1 |
|
increases expression |
ISO |
5 |
42,799,982 |
42,812,024 |
RGD:6480464 |
CTD |
| G |
SEPP1 |
selenoprotein P, plasma, 1 |
|
increases secretion |
ISO |
5 |
42,799,982 |
42,812,024 |
RGD:6480464 |
CTD |
| G |
SEPP1 |
selenoprotein P, plasma, 1 |
|
multiple interactions |
ISO |
5 |
42,799,982 |
42,812,024 |
RGD:6480464 |
CTD |
| G |
SLC6A4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
increases expression |
ISO |
17 |
28,523,376 |
28,562,954 |
RGD:6480464 |
CTD |
| G |
SLC7A6 |
solute carrier family 7 (amino acid transporter light chain, y+L system), member 6 |
|
multiple interactions |
ISO |
16 |
68,298,419 |
68,335,726 |
RGD:6480464 |
CTD |
| G |
SLC9A3 |
solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 |
|
increases expression |
ISO |
5 |
473,334 |
524,549 |
RGD:6480464 |
CTD |
| G |
SLC9A3 |
solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 |
|
increases expression |
EXP |
5 |
473,334 |
524,549 |
RGD:6480464 |
CTD |
| G |
SLCO1A2 |
solute carrier organic anion transporter family, member 1A2 |
|
multiple interactions |
ISO |
12 |
21,417,534 |
21,548,371 |
RGD:6480464 |
CTD |
| G |
SLCO1A2 |
solute carrier organic anion transporter family, member 1A2 |
|
affects expression |
ISO |
12 |
21,417,534 |
21,548,371 |
RGD:6480464 |
CTD |
| G |
SLCO1A2 |
solute carrier organic anion transporter family, member 1A2 |
|
increases expression |
ISO |
12 |
21,417,534 |
21,548,371 |
RGD:6480464 |
CTD |
| G |
SLCO1A2 |
solute carrier organic anion transporter family, member 1A2 |
|
increases expression |
ISO |
12 |
21,417,534 |
21,548,371 |
RGD:6480464 |
CTD |
| G |
SLCO1B3 |
solute carrier organic anion transporter family, member 1B3 |
|
decreases expression |
ISO |
12 |
20,963,638 |
21,069,845 |
RGD:6480464 |
CTD |
| G |
SLCO1B3 |
solute carrier organic anion transporter family, member 1B3 |
|
decreases expression |
ISO |
12 |
20,963,638 |
21,069,845 |
RGD:6480464 |
CTD |
| G |
SLCO1B3 |
solute carrier organic anion transporter family, member 1B3 |
|
multiple interactions |
ISO |
12 |
20,963,638 |
21,069,845 |
RGD:6480464 |
CTD |
| G |
SLCO2A1 |
solute carrier organic anion transporter family, member 2A1 |
|
decreases expression |
ISO |
3 |
133,651,540 |
133,748,920 |
RGD:6480464 |
CTD |
| G |
SLCO2B1 |
solute carrier organic anion transporter family, member 2B1 |
|
decreases expression |
ISO |
11 |
74,862,032 |
74,917,445 |
RGD:6480464 |
CTD |
| G |
SLCO4C1 |
solute carrier organic anion transporter family, member 4C1 |
|
multiple interactions |
EXP |
5 |
101,569,690 |
101,632,253 |
RGD:6480464 |
CTD |
| G |
SLPI |
secretory leukocyte peptidase inhibitor |
|
multiple interactions |
ISO |
20 |
43,880,879 |
43,883,206 |
RGD:6480464 |
CTD |
| G |
SMAD3 |
SMAD family member 3 |
|
affects expression |
ISO |
15 |
67,358,195 |
67,487,533 |
RGD:6480464 |
CTD |
| G |
SMOC2 |
SPARC related modular calcium binding 2 |
|
decreases expression |
ISO |
6 |
168,841,831 |
169,068,674 |
RGD:6480464 |
CTD |
| G |
SMOC2 |
SPARC related modular calcium binding 2 |
|
multiple interactions |
ISO |
6 |
168,841,831 |
169,068,674 |
RGD:6480464 |
CTD |
| G |
SOCS1 |
suppressor of cytokine signaling 1 |
|
increases expression |
EXP |
16 |
11,348,274 |
11,350,039 |
RGD:6480464 |
CTD |
| G |
SOD1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
ISO |
21 |
33,031,935 |
33,041,244 |
RGD:6480464 |
CTD |
| G |
SOD1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
ISO |
21 |
33,031,935 |
33,041,244 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
ISO |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
ISO |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD3 |
superoxide dismutase 3, extracellular |
|
multiple interactions |
ISO |
4 |
24,797,085 |
24,802,467 |
RGD:6480464 |
CTD |
| G |
SOST |
sclerostin |
|
multiple interactions |
EXP |
17 |
41,831,099 |
41,836,156 |
RGD:6480464 |
CTD |
| G |
SOX11 |
SRY (sex determining region Y)-box 11 |
|
decreases expression |
ISO |
2 |
5,832,799 |
5,841,517 |
RGD:6480464 |
CTD |
| G |
SOX2 |
SRY (sex determining region Y)-box 2 |
|
multiple interactions |
ISO |
3 |
181,429,712 |
181,432,224 |
RGD:6480464 |
CTD |
| G |
SOX9 |
SRY (sex determining region Y)-box 9 |
|
multiple interactions |
EXP |
17 |
70,117,161 |
70,122,561 |
RGD:6480464 |
CTD |
| G |
TJAP1 |
tight junction associated protein 1 (peripheral) |
|
decreases expression |
ISO |
6 |
43,445,261 |
43,474,294 |
RGD:6480464 |
CTD |
| G |
TJAP1 |
tight junction associated protein 1 (peripheral) |
|
multiple interactions |
ISO |
6 |
43,445,261 |
43,474,294 |
RGD:6480464 |
CTD |
| G |
TLE4 |
transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) |
|
decreases expression |
EXP |
9 |
82,186,878 |
82,341,656 |
RGD:6480464 |
CTD |
| G |
TLR3 |
toll-like receptor 3 |
|
decreases expression |
EXP |
4 |
186,990,309 |
187,006,252 |
RGD:6480464 |
CTD |
| G |
TMC5 |
transmembrane channel-like 5 |
|
multiple interactions |
EXP |
16 |
19,422,057 |
19,510,435 |
RGD:6480464 |
CTD |
| G |
TNC |
tenascin C |
|
multiple interactions |
EXP |
9 |
117,781,854 |
117,880,536 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
decreases activity |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
decreases expression |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
decreases expression |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
UGT2A1 |
UDP glucuronosyltransferase 2 family, polypeptide A1, complex locus |
|
affects expression |
ISO |
4 |
70,454,135 |
70,518,967 |
RGD:6480464 |
CTD |
| G |
UGT2B4 |
UDP glucuronosyltransferase 2 family, polypeptide B4 |
|
affects expression |
ISO |
4 |
70,345,883 |
70,361,626 |
RGD:6480464 |
CTD |
| G |
UGT2B4 |
UDP glucuronosyltransferase 2 family, polypeptide B4 |
|
increases expression |
ISO |
4 |
70,345,883 |
70,361,626 |
RGD:6480464 |
CTD |
| G |
USP3 |
ubiquitin specific peptidase 3 |
|
increases expression |
ISO |
15 |
63,796,710 |
63,886,839 |
RGD:6480464 |
CTD |
| G |
VANGL1 |
VANGL planar cell polarity protein 1 |
|
decreases expression |
ISO |
1 |
116,184,574 |
116,240,845 |
RGD:6480464 |
CTD |
| G |
VANGL1 |
VANGL planar cell polarity protein 1 |
|
multiple interactions |
ISO |
1 |
116,184,574 |
116,240,845 |
RGD:6480464 |
CTD |
| G |
VASP |
vasodilator-stimulated phosphoprotein |
|
decreases expression |
ISO |
19 |
46,010,688 |
46,030,241 |
RGD:6480464 |
CTD |
| G |
VASP |
vasodilator-stimulated phosphoprotein |
|
multiple interactions |
ISO |
19 |
46,010,688 |
46,030,241 |
RGD:6480464 |
CTD |
| G |
VCAM1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
EXP |
1 |
101,185,196 |
101,204,601 |
RGD:6480464 |
CTD |
| G |
VCAM1 |
vascular cell adhesion molecule 1 |
|
decreases expression |
EXP |
1 |
101,185,196 |
101,204,601 |
RGD:6480464 |
CTD |
| G |
VCAM1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
ISO |
1 |
101,185,196 |
101,204,601 |
RGD:6480464 |
CTD |
| G |
VCAM1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
ISO |
1 |
101,185,196 |
101,204,601 |
RGD:6480464 |
CTD |
| G |
VCAN |
versican |
|
multiple interactions |
ISO |
5 |
82,767,493 |
82,878,122 |
RGD:6480464 |
CTD |
| G |
VDR |
vitamin D (1,25- dihydroxyvitamin D3) receptor |
|
increases expression |
ISO |
12 |
48,235,320 |
48,298,814 |
RGD:6480464 |
CTD |
| G |
VDR |
vitamin D (1,25- dihydroxyvitamin D3) receptor |
|
multiple interactions |
ISO |
12 |
48,235,320 |
48,298,814 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
multiple interactions |
EXP |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
decreases secretion |
EXP |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
decreases expression |
ISO |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
WFDC1 |
WAP four-disulfide core domain 1 |
|
decreases expression |
ISO |
16 |
84,328,401 |
84,363,450 |
RGD:6480464 |
CTD |
| G |
WFS1 |
Wolfram syndrome 1 (wolframin) |
|
increases expression |
EXP |
4 |
6,271,577 |
6,304,992 |
RGD:6480464 |
CTD |
| G |
WIF1 |
WNT inhibitory factor 1 |
|
multiple interactions |
EXP |
12 |
65,444,404 |
65,515,346 |
RGD:6480464 |
CTD |
Term paths to the root
|